Pfizer (PFE) 10-Q 7 May 20 2020 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 29, 2020	May 04, 2020
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 29, 2020
Document Transition Report	false
Entity File Number	1-3619
Entity Registrant Name	PFIZER INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-5315170
Entity Address, Address Line One	235 East 42nd Street
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10017
City Area Code	212
Local Phone Number	733-2323
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,554,833,754
Entity Central Index Key	0000078003
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Common Stock, $.05 par value [Member]
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, $.05 par value
Trading Symbol	PFE
Security Exchange Name	NYSE
0.250% Notes due 2022 [Member]
Entity Information [Line Items]
Title of 12(b) Security	0.250% Notes due 2022
Trading Symbol	PFE22
Security Exchange Name	NYSE
1.000% Notes due 2027 [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.000% Notes due 2027
Trading Symbol	PFE27
Security Exchange Name	NYSE

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Millions, $ in Millions		3 Months Ended
		Mar. 29, 2020	Mar. 31, 2019
Income Statement [Abstract]
Revenues	[1]	$ 12,028	$ 13,118
Costs and expenses:
Cost of sales	[1],[2]	2,378	2,433
Selling, informational and administrative expenses	[1],[2]	2,873	3,339
Research and development expenses	[1],[2]	1,724	1,703
Amortization of intangible assets	[1]	885	1,183
Restructuring charges and certain acquisition-related costs	[1]	69	46
(Gain) on completion of Consumer Healthcare JV transaction	[1]	(6)	0
Other (income)/deductions––net	[1]	221	92
Income from continuing operations before provision for taxes on income	[1],[3]	3,885	4,323
Provision for taxes on income	[1]	475	433
Income from continuing operations	[1]	3,410	3,889
Discontinued operations––net of tax	[1]	0	0
Net income before allocation to noncontrolling interests	[1],[4],[5],[6]	3,410	3,889
Less: Net income attributable to noncontrolling interests	[1]	9	6
Net income attributable to Pfizer Inc.	[1]	$ 3,401	$ 3,884
Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	$ 0.61	$ 0.69
Discontinued operations––net of tax (in dollars per share)	[1]	0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	0.61	0.69
Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	0.61	0.68
Discontinued operations––net of tax (in dollars per share)	[1]	0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	$ 0.61	$ 0.68
Weighted-average shares––basic	[1]	5,545	5,635
Weighted-average shares––diluted	[1]	5,613	5,750
[1]	Amounts may not add due to rounding.
[2]	Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
[3]	Income from continuing operations before provision for taxes on income . Biopharma’s earnings include d ividend income of $77 million in the first quarter of 2020 and $64 million in the first quarter of 2019 from our investment in ViiV. For additional information, see Note 4.
[4]	Amounts may not add due to rounding.
[5]	Amounts may not add due to rounding.
[6]	Amounts may not add due to rounding.

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Millions		3 Months Ended
		Mar. 29, 2020	Mar. 31, 2019
Statement of Comprehensive Income [Abstract]
Net income before allocation to noncontrolling interests	[1],[2],[3],[4]	$ 3,410	$ 3,889
Foreign currency translation adjustments, net	[2],[5]	(1,272)	324
Reclassification adjustments	[2]	0	2
Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax	[2]	(1,272)	326
Unrealized holding gains/(losses) on derivative financial instruments, net	[2]	(501)	267
Reclassification adjustments for (gains)/losses included in net income	[2],[6]	19	(263)
Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total	[2]	(482)	4
Unrealized holding gains/(losses) on available-for-sale securities, net	[2]	(51)	40
Reclassification adjustments for losses included in net income	[2],[6]	15	11
Other comprehensive income (loss), available-for-sale securities, before tax, total	[2]	(36)	51
Benefit plans: actuarial losses, net	[2]	(166)	0
Reclassification adjustments related to amortization	[2]	66	60
Reclassification adjustments related to settlements, net	[2]	53	0
Other	[2]	16	(23)
Defined benefit plan, amounts recognized in other comprehensive income (loss), net gain (loss), before tax, total	[2]	(31)	37
Reclassification adjustments related to amortization of prior service costs and other, net	[2]	(45)	(46)
Other	[2]	(1)	0
Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax	[2]	(45)	(46)
Other comprehensive income/(loss), before tax	[2]	(1,867)	372
Tax provision/(benefit) on other comprehensive income/(loss)	[2]	(377)	25
Other comprehensive income/(loss) before allocation to noncontrolling interests	[2],[3]	(1,490)	348
Comprehensive income before allocation to noncontrolling interests	[2]	1,920	4,237
Less: Comprehensive income attributable to noncontrolling interests	[2]	9	1
Comprehensive income attributable to Pfizer Inc.	[2]	$ 1,911	$ 4,236
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	Amounts may not add due to rounding.
[5]	Amounts in the first quarter of 2020 include a loss of approximately $1.6 billion pre-tax ( $1.2 billion after-tax) related to foreign currency translation adjustments attributable to our equity method investment in the GSK Consumer Healthcare joint venture (see Note 2B ) , partially offset by the results of our net investment hedging program.
[6]	Reclassified into Other (income)/deductions—net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Other (income)/deductions—net and Cost of sales, see Note 7E. Financial Instruments: Derivative Financial Instruments and Hedging Activities.

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - Parenthetical $ in Millions	3 Months Ended
	Mar. 29, 2020USD ($)
Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax	$ (1,272)	[1]
GSK Consumer Healthcare [Member]
Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax	(1,600)
Other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax	$ (1,200)
[1]	Amounts may not add due to rounding.

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions		Mar. 29, 2020	Dec. 31, 2019
Assets
Cash and cash equivalents	[1]	$ 2,151	$ 1,305	[2]
Short-term investments	[1]	8,199	8,525
Trade accounts receivable, less allowance for doubtful accounts: 2020—$527; 2019—$527	[1]	9,881	8,724
Inventories	[1],[3]	8,423	8,283
Current tax assets	[1]	3,346	3,344
Other current assets	[1]	2,737	2,622
Total current assets	[1]	34,738	32,803
Equity-method investments	[1]	15,524	17,133
Long-term investments	[1]	2,696	3,014
Property, plant and equipment, less accumulated depreciation: 2020—$16,929; 2019—$16,789	[1]	14,040	13,967
Identifiable intangible assets, less accumulated amortization	[1],[4]	34,464	35,370
Goodwill	[1]	58,502	58,653
Noncurrent deferred tax assets and other noncurrent tax assets	[1]	2,207	2,099
Other noncurrent assets	[1]	4,166	4,450
Total assets	[1]	166,336	167,489
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2020—$337; 2019—$1,462	[1]	16,007	16,195
Trade accounts payable	[1]	3,972	4,220
Dividends payable	[1]	0	2,104
Income taxes payable	[1]	1,150	980
Accrued compensation and related items	[1]	2,246	2,720
Other current liabilities	[1]	10,515	11,083
Total current liabilities	[1]	33,890	37,304
Long-term debt	[1]	36,281	35,955
Pension benefit obligations, net	[1]	5,442	5,638
Postretirement benefit obligations, net	[1]	1,093	1,124
Noncurrent deferred tax liabilities	[1]	5,268	5,578
Other taxes payable	[1]	12,212	12,126
Other noncurrent liabilities	[1]	6,812	6,317
Total liabilities	[1]	100,998	104,042
Commitments and Contingencies	[1]
Preferred stock	[1]	17	17
Common stock	[1]	470	468
Additional paid-in capital	[1]	87,680	87,428
Treasury stock	[1]	(111,010)	(110,801)
Retained earnings	[1]	101,000	97,670
Accumulated other comprehensive loss	[1]	(13,131)	(11,640)
Total Pfizer Inc. shareholders’ equity	[1]	65,026	63,143
Equity attributable to noncontrolling interests	[1]	312	303
Total equity	[1],[5]	65,338	63,447
Total liabilities and equity	[1]	$ 166,336	$ 167,489
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	The change from December 31, 2019 reflects increases for certain products, including inventory build for new product launches, market demand and network strategy, partially offset by a decrease due to foreign exchange.
[4]	The decrease in I dentifiable intangible assets, less accumulated amortization , is primarily due to amortization.
[5]	Amounts may not add due to rounding.

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($) $ in Millions		Mar. 29, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	[1]	$ 527	$ 527
Property, plant and equipment, accumulated depreciation	[1]	16,929	16,789
Current portion of long-term debt	[1]	$ 337	$ 1,462
[1]	Amounts may not add due to rounding.

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) - USD ($) $ in Millions		Total		Preferred Stock [Member]	Common Stock [Member]	Add'l Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accum. Other Comp. Loss [Member]	Shareholders' Equity [Member]	Noncontrolling Interests [Member]
Beginning balance (in shares) at Dec. 31, 2018	[1]			(478)	(9,332,000,000)		(3,615,000,000)
Beginning balance at Dec. 31, 2018	[1]	$ 63,758		$ 19	$ 467	$ 86,253	$ (101,610)	$ 89,554	$ (11,275)	$ 63,407	$ 351
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	3,889	[2],[3],[4]					3,884		3,884	6
Other comprehensive income/(loss), net of tax	[1]	348	[3]						353	353	(4)
Cash dividends declared:
Common stock	[1]	(68)						(68)		(68)
Preferred stock	[1]	0						0		0
Noncontrolling interests	[1]	0
Share-based payment transactions (in shares)	[1]				26,000,000		7,000,000
Share-based payment transactions	[1]	78			$ 1	383	$ (306)			78
Purchases of common stock (in shares)	[1]						(180,000,000)
Purchases of common stock	[1]	(8,865)					$ (8,865)			(8,865)
Preferred stock conversions and redemptions (in shares)	[1]			(12)
Preferred stock conversions and redemptions	[1]	(1)		$ 0		(1)				(1)
Other	[1],[5]	19						19		19
Ending balance (in shares) at Mar. 31, 2019	[1]			(466)	(9,358,000,000)		(3,801,000,000)
Ending balance at Mar. 31, 2019	[1]	59,158		$ 19	$ 468	86,635	$ (110,781)	93,388	(10,923)	58,806	352
Beginning balance (in shares) at Dec. 31, 2019	[1]			(431)	(9,369,000,000)		(3,835,000,000)
Beginning balance at Dec. 31, 2019	[1]	63,447	[6]	$ 17	$ 468	87,428	$ (110,801)	97,670	(11,640)	63,143	303
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[1]	3,410	[2],[3],[4]					3,401		3,401	9
Other comprehensive income/(loss), net of tax	[1]	(1,490)	[3]						(1,490)	(1,490)	0
Cash dividends declared:
Common stock	[1]	(71)						(71)		(71)
Preferred stock	[1]	0						0		0
Noncontrolling interests	[1]	0
Share-based payment transactions (in shares)	[1]				23,000,000		6,000,000
Share-based payment transactions	[1]	44			$ 1	252	$ (209)			44
Purchases of common stock (in shares)	[1]						0
Purchases of common stock	[1]	0					$ 0
Preferred stock conversions and redemptions (in shares)	[1]			(14)
Preferred stock conversions and redemptions	[1]	(1)		$ (1)		(1)	$ 0			(1)
Other (in shares)	[1]						0
Other	[1]	0				0		0		0	0
Ending balance (in shares) at Mar. 29, 2020	[1]			(417)	(9,393,000,000)		(3,841,000,000)
Ending balance at Mar. 29, 2020	[1]	$ 65,338	[6]	$ 17	$ 470	$ 87,680	$ (111,010)	$ 101,000	$ (13,131)	$ 65,026	$ 312
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	Amounts may not add due to rounding.
[5]	The increase to Retained earnings represents the cumulative effect of the adoption of a new accounting standard in the first quarter of 2019 for leases. For additional information, see Notes to Consolidated Financial Statements–– Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2019 in our 2019 Financial Report.
[6]	Amounts may not add due to rounding.

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Millions		3 Months Ended
		Mar. 29, 2020	Mar. 31, 2019
Operating Activities
Net income before allocation to noncontrolling interests	[1],[2],[3],[4]	$ 3,410	$ 3,889
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization	[4]	1,218	1,545
Asset write-offs and impairments	[4]	45	155
TCJA impact	[4],[5]	0	(131)
Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed	[4]	(6)	0
Deferred taxes from continuing operations	[4]	109	(60)
Share-based compensation expense	[4]	64	185
Benefit plan contributions in excess of expense/income	[4]	(248)	(151)
Other adjustments, net	[4]	123	(236)
Other changes in assets and liabilities, net of acquisitions and divestitures	[4]	(1,581)	(3,498)
Net cash provided by operating activities	[4]	3,133	1,698
Investing Activities
Purchases of property, plant and equipment	[4]	(463)	(460)
Purchases of short-term investments	[4]	(2,551)	(1,402)
Proceeds from redemptions/sales of short-term investments	[4]	3,257	3,601
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less	[4]	(416)	5,941
Purchases of long-term investments	[4]	(22)	(84)
Proceeds from redemptions/sales of long-term investments	[4]	152	44
Acquisitions of intangible assets	[4]	(32)	(158)
Other investing activities, net	[4]	4	67
Net cash provided by/(used in) investing activities	[4]	(71)	7,550
Financing Activities
Proceeds from short-term borrowings	[4]	5,302	609
Principal payments on short-term borrowings	[4]	(7,551)	(1,766)
Net proceeds from short-term borrowings with original maturities of three months or less	[4]	3,207	2,032
Proceeds from issuance of long-term debt	[4]	1,241	4,942
Principal payments on long-term debt	[4]	(2,181)	(3,004)
Purchases of common stock	[4]	0	(8,865)
Cash dividends paid	[4]	(2,105)	(2,045)
Proceeds from exercise of stock options	[4]	124	126
Other financing activities, net	[4]	(237)	(495)
Net cash used in financing activities	[4]	(2,200)	(8,467)
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents	[4]	(15)	12
Net increase in cash and cash equivalents and restricted cash and cash equivalents	[4]	846	792
Cash and cash equivalents and restricted cash and cash equivalents, beginning	[4]	1,350	1,225
Cash and cash equivalents and restricted cash and cash equivalents, end	[4]	2,196	2,018
Cash paid (received) during the period for:
Income taxes	[4]	239	235
Interest paid	[4]	472	385
Interest rate hedges	[4]	$ (11)	$ (33)
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	Amounts may not add due to rounding.
[5]	As a result of the enactment of the TCJA in December 2017, Pfizer’s Provision for taxes on income for the three months ended March 31, 2019 was favorably impacted by approximately $131 million , primarily as a result of additional guidance issued by the U.S. Department of Treasury.

CONDENSED CONSOLIDATED STATEM_6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (PARENTHETICAL) - USD ($) $ in Millions		3 Months Ended
		Mar. 29, 2020	Mar. 31, 2019
Statement of Cash Flows [Abstract]
TCJA impact	[1],[2]	$ 0	$ (131)
[1]	Amounts may not add due to rounding.
[2]	As a result of the enactment of the TCJA in December 2017, Pfizer’s Provision for taxes on income for the three months ended March 31, 2019 was favorably impacted by approximately $131 million , primarily as a result of additional guidance issued by the U.S. Department of Treasury.

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Mar. 29, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Significant Accounting Policies	Basis of Presentation and Significant Accounting Policies A. Basis of Presentation See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes in this Quarterly Report on Form 10-Q. We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three months ended February 23, 2020 and February 24, 2019 . The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three months ended March 29, 2020 and March 31, 2019 . Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year. We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2019 Financial Report. At the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new global structure consisting of three business segments––Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and through July 31, 2019 , Consumer Healthcare. Biopharma and Upjohn are the only reportable segments. For additional information, see Note 13 . Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan). As a result, revenues and expenses associated with Meridian and Mylan-Japan are reported in our Upjohn business beginning in the first quarter of 2020. In 2019, revenues and expenses from Meridian and Mylan-Japan were recorded in our Biopharma business. We performed certain reclassifications between the Biopharma and Upjohn segments to conform 2019 segment revenues and expenses associated with Meridian and Mylan-Japan to the current presentation. There was no impact to our consolidated financial statements. For additional information, see Note 13. As described in Notes to Consolidated Financial Statements— Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation in our 2019 Financial Report, recent acquisitions and the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture have impacted our results of operations. For additional information on the GSK Consumer Healthcare joint venture, see Note 2. Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts. In the first quarter of 2020 , as of January 1, 2020 , we adopted four new accounting standards. See Note 1B for further information. B. Adoption of New Accounting Standards in 2020 On January 1, 2020 , we adopted four new accounting standards. Credit Losses on Financial Instruments ––We adopted a new accounting standard for credit losses on financial instruments, which replaces the probable initial recognition threshold for incurred loss estimates under prior guidance with a methodology that reflects expected credit loss estimates. The standard generally impacts financial assets that have a contractual right to receive cash and are not accounted for at fair value through net income, such as accounts receivable and held-to-maturity debt securities. The new guidance requires us to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for certain financial instruments, using information such as historical experience, current economic conditions and information, and the use of reasonable and supportable forecasted information. The standard also amends existing impairment guidance for available-for-sale debt securities to incorporate a credit loss allowance and allows for reversals of credit impairments in the event the issuer’s credit improves. We adopted the new accounting standard utilizing the modified retrospective method and, therefore, no adjustments were made to amounts in our prior period financial statements. The cumulative effect of adopting the standard as an adjustment to the opening balance of Retained earnings was not material. The impact of adoption did not have a material impact on our condensed consolidated statement of income or condensed consolidated statement of cash flows for the three months ended March 29, 2020 , nor on our condensed consolidated balance sheet as of March 29, 2020 . For additional information, see Note 1C . Goodwill Impairment Testing ––We prospectively adopted the new standard, which eliminates the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. Under the new guidance, the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, and recognizing an impairment charge for the amount by which the carrying amount of the reporting unit exceeds its fair value. There was no impact to our condensed consolidated financial statements from the adoption of this new standard. Implementation Costs in a Cloud Computing Arrangement ––We prospectively adopted the new standard related to customers’ accounting for implementation costs incurred in a cloud computing arrangement that is considered a service contract. The new guidance aligns the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The adoption of this guidance did not have a material impact on our condensed consolidated financial statements. Collaboration Agreements ––We prospectively adopted the new standard, which provides new guidance clarifying the interaction between the accounting for collaborative arrangements and revenue from contracts with customers. There was no impact to our condensed consolidated financial statements from the adoption of this new standard. On January 1, 2019, we adopted four new accounting standards. For additional information, see Notes to Consolidated Financial Statements–– Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2019 included in our 2019 Financial Report. C. Revenues and Trade Accounts Receivable Deductions from Revenues–– Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled $5.6 billion as of March 29, 2020 and $5.7 billion as of December 31, 2019 . The following table provides information about the balance sheet classification of these accruals: (MILLIONS OF DOLLARS) March 29, December 31, 2019 Reserve against Trade accounts receivable, less allowance for doubtful accounts $ 1,107 $ 1,257 Other current liabilities : Accrued rebates 3,408 3,285 Other accruals 553 581 Other noncurrent liabilities 577 565 Total accrued rebates and other accruals $ 5,645 $ 5,689 Trade Accounts Receivable–– Trade accounts receivable are stated at their net realizable value. The allowance for credit losses against gross trade accounts receivable reflects the best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables. In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted. During the first quarter of 2020 , additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements.

Acquisition and Equity-Method I

Acquisition and Equity-Method Investment	3 Months Ended
	Mar. 29, 2020
Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]
Acquisition and Equity-Method Investment	Acquisition and Equity-Method Investment A. Acquisition Array BioPharma Inc. On July 30, 2019 , we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for $48 per share in cash. The total fair value of the consideration transferred for Array was approximately $11.2 billion ( $10.9 billion , net of cash acquired). Array’s portfolio includes the approved combined use of Braftovi (encorafenib) and Mektovi (binimetinib) for the treatment of BRAF V600E - or BRAF V600K -mutant unresectable or metastatic melanoma. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not yet been finalized. B. Equity-Method Investment Formation of GSK Consumer Healthcare Joint Venture On July 31, 2019 , we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name. In exchange for contributing our Consumer Healthcare business to the joint venture, we received a 32% equity stake in the new company and GSK owns the remaining 68% . Upon the closing of the transaction, we deconsolidated our Consumer Healthcare business and recognized a pre-tax gain of $8.1 billion ( $5.4 billion , net of tax) in our fiscal third quarter of 2019 in (Gain) on completion of Consumer Healthcare JV transaction for the difference in the fair value of our 32% equity stake in the new company and the carrying value of our Consumer Healthcare business. We may record additional adjustments to the gain in future periods, which we do not expect to have a material impact on our consolidated financial statements. We are accounting for our interest in GSK Consumer Healthcare as an equity-method investment. The carrying value of our investment in GSK Consumer Healthcare is approximately $15.4 billion as of March 29, 2020 and $17.0 billion as of December 31, 2019 and is reported as a private equity investment in the Equity-method investments line in our condensed consolidated balance sheet. We record our share of earnings from the GSK Consumer Healthcare joint venture on a quarterly basis on a one-quarter lag in Other (income)/deductions––net commencing from August 1, 2019. Therefore, we recorded our share of the joint venture’s earnings generated in the fourth quarter of 2019, which totaled approximately $11 million , in our operating results in the first quarter of 2020 (see Note 4 ). As of the July 31, 2019 closing date, we estimated that the fair value of our investment in GSK Consumer Healthcare was approximately $15.7 billion and that 32% of the underlying equity in the carrying value of the net assets of GSK Consumer Healthcare was approximately $11.2 billion , resulting in an initial basis difference of approximately $4.5 billion . In the fourth quarter of 2019, we preliminarily completed the allocation of the basis difference, which resulted from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the joint venture, primarily to inventory, definite-lived intangible assets, indefinite-lived intangible assets, related deferred tax liabilities and equity method goodwill within the investment account. We recorded the amortization of basis differences allocated to inventory, definite-lived intangible assets and related deferred tax liabilities in Other (income)/deductions––net commencing August 1, 2019. During the fourth quarter of 2019, GSK Consumer Healthcare revised the initial carrying value of the net assets of the joint venture and our 32% share of the underlying equity in the carrying value of the net assets of GSK Consumer Healthcare was reduced to approximately $11.0 billion and our initial basis difference was increased to approximately $4.8 billion . The adjustment was allocated to equity method goodwill within the investment account. The amortization of these basis differences for the fourth quarter of 2019 totaling approximately $44 million of expense is included in our operating results in Other (income)/deductions––net in the first quarter of 2020 (see Note 4 ). Amortization of basis differences on inventory and related deferred tax liabilities has been completely recognized by the first quarter of 2020. Basis differences on definite-lived intangible assets and related deferred tax liabilities are being amortized over approximately 17 years . GSK Consumer Healthcare is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in Other comprehensive income . The decrease in the value of our investment from December 31, 2019 to March 29, 2020 is primarily due to foreign currency translation adjustments (see Note 6 ). As a part of Pfizer, pre-tax income on a management business unit basis for the Consumer Healthcare business was $281 million for the three months ended March 31, 2019 . Summarized financial information for our equity method investee, GSK Consumer Healthcare, as of and for the three months ending December 31, 2019, the most recent period available, is as follows: (MILLIONS OF DOLLARS) December 31, Current assets $ 7,537 Noncurrent assets 39,509 Total assets $ 47,046 Current liabilities $ 5,576 Noncurrent liabilities 5,321 Total liabilities $ 10,898 Equity attributable to shareholders $ 36,029 Equity attributable to noncontrolling interests 120 Total net equity $ 36,149 (MILLIONS OF DOLLARS) Three Months Ended December 31, 2019 Net sales $ 3,188 Cost of sales (1,811 ) Gross profit $ 1,377 Income from continuing operations 46 Net income 46 Income attributable to shareholders 37

Restructuring Charges and Other

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	3 Months Ended
	Mar. 29, 2020
Restructuring and Related Activities [Abstract]
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example: • In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and • In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems. All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and R&D, as well as groups such as information technology, shared services and corporate operations. Transforming to a More Focused Company With the formation of the GSK Consumer Healthcare venture and the anticipated combination of Upjohn, our global, primarily off-patent branded and generics business, with Mylan, Pfizer is transforming itself into a more focused, global leader in science-based innovative medicines. As a result, we began in the fourth quarter of 2019, to identify and undertake efforts to ensure our cost base aligns appropriately with our Biopharmaceutical revenue base as a result of both the completed GSK Consumer Healthcare and expected Upjohn transactions. While certain direct costs have transferred or will transfer to the GSK Consumer Healthcare joint venture and to the Upjohn entities, there are indirect costs which are not expected to transfer. In addition, we are taking steps to restructure our organizations to appropriately support and drive the purpose of the three core functions of our focused innovative medicines business: R&D, Manufacturing and Commercial. We expect the costs associated with this multi-year effort to continue through 2022 and to total approximately $1.2 billion on a pre-tax basis with approximately 10% of the costs to be non-cash. Actions may include, among others, changes in location of certain activities, expanded use and co-location of centers of excellence and shared services, and increased use of digital technologies. The associated actions and the specific costs are currently in development but will include severance and benefit plan impacts, exit costs as well as associated implementation costs. From the start of this initiative in the fourth quarter of 2019 through March 29, 2020 , we incurred approximately $160 million associated with this initiative. Current-Period Key Activities For the first three months of 2020 , we incurred costs of $117 million composed primarily of the Transforming to a More Focused Company initiative. For the first three months of 2019, we incurred costs of $92 million composed primarily of the 2017-2019 and Organizing for Growth initiatives that were substantially completed as of year-end 2019. The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives: Three Months Ended (MILLIONS OF DOLLARS) March 29, March 31, Restructuring charges/(credits): Employee terminations $ 25 $ (2 ) Asset impairments 31 9 Exit costs — 3 Restructuring charges (a) 56 10 Transaction costs (b) 3 — Integration costs and other (c) 10 36 Restructuring charges and certain acquisition-related costs 69 46 Net periodic benefit costs recorded in Other (income)/deductions––net 24 6 Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income as follows (d) : Cost of sales 5 9 Selling, informational and administrative expenses — 1 Research and development expenses (5 ) 3 Total additional depreciation––asset restructuring — 13 Implementation costs recorded in our condensed consolidated statements of income as follows (e) : Cost of sales 10 13 Selling, informational and administrative expenses 15 9 Research and development expenses — 4 Total implementation costs 24 26 Total costs associated with acquisitions and cost-reduction/productivity initiatives $ 117 $ 92 (a) In the first quarter of 2020 , restructuring charges mainly represent asset write-downs and employee termination costs associated with cost reduction initiatives. In the first quarter of 2019 , restructuring charges were primarily associated with cost reduction initiatives and mainly represent asset write-downs, partially offset by the reversal of previously recorded accruals for employee termination costs and asset impairments related to our acquisition of Hospira. The restructuring activities for the first quarter of 2020 are associated with the following: • Biopharma ( $2 million charge); Upjohn ( $13 million charge); and Other ( $41 million charge). The restructuring activities for the first quarter of 2019 are associated with the following: • Biopharma ( $13 million charge); Upjohn ( $13 million credit); and Other ( $10 million charge). (b) Transaction costs represent external costs for banking, legal, accounting and other similar services. In the first quarter of 2020, transaction costs relate to our acquisition of Array. (c) Integration costs and other represent external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the first quarter of 2020 , integration costs and other were mostly related to our acquisition of Array. In the first quarter of 2019 , integration costs and other were primarily related to our acquisition of Hospira. (d) Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions. (e) Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives. The following table provides the components of and changes in our restructuring accruals: (MILLIONS OF DOLLARS) Employee Termination Costs Asset Impairment Charges Exit Costs Accrual Balance, December 31, 2019 (a) $ 887 $ — $ 46 $ 933 Provision 25 31 — 56 Utilization and other (b) (243 ) (31 ) (1 ) (275 ) Balance, March 29, 2020 (c) $ 669 $ — $ 45 $ 714 (a) Included in Other current liabilities ( $714 million ) and Other noncurrent liabilities ( $219 million ). (b) Includes adjustments for foreign currency translation. (c) Included in Other current liabilities ( $532 million ) and Other noncurrent liabilities ( $182 million ).

Other (Income)_Deductions - Net

Other (Income)/Deductions - Net	3 Months Ended
	Mar. 29, 2020
Other Income and Expenses [Abstract]
Other (Income)/Deductions - Net	Other (Income)/Deductions—Net The following table provides components of Other (income)/deductions––net : Three Months Ended (MILLIONS OF DOLLARS) March 29, March 31, Interest income (a) $ (34 ) $ (66 ) Interest expense (a) 390 361 Net interest expense 356 295 Royalty-related income (119 ) (89 ) Net (gains)/losses on asset disposals 1 (1 ) Net (gains)/losses recognized during the period on equity securities (b) 255 (111 ) Income from collaborations, out-licensing arrangements and sales of compound/product rights (c) (115 ) (82 ) Net periodic benefit credits other than service costs (d) (67 ) (40 ) Certain legal matters, net 10 4 Certain asset impairments (e) — 150 Business and legal entity alignment costs (f) — 119 Net losses on early retirement of debt — 138 GSK Consumer Healthcare JV equity method (income)/loss (g) 33 — Other, net (h) (132 ) (291 ) Other (income)/deductions––net $ 221 $ 92 (a) Interest income decreased in the first quarter of 2020 , primarily driven by a lower investment balance and lower short-term interest rates. Interest expense increased in the first quarter of 2020 , mainly as a result of an increased commercial paper balance due to the acquisition of Array. (b) The losses in the first quarter of 2020 , include, among other things, unrealized losses of $134 million related to our investment in Allogene. The gains in the first quarter of 2019 included, among other things, unrealized gains of $43 million related to our investment in Allogene. For additional information on investments, see Note 7B . (c) Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In the first quarter of 2020 , mainly includes, among other things, an upfront payment to us of $75 million from our sale of our CK1 assets to Biogen, Inc. In the first quarter of 2019 , primarily included $60 million in milestone income from Mylan Pharmaceuticals Inc. related to the FDA’s approval and launch of Wixela Inhub ® , a generic of Advair Diskus ® . (d) For additional information, see Note 10 . (e) In the first quarter of 2019 , primarily included intangible asset impairment charges of $130 million composed of: (i) $90 million related to WRDM IPR&D, for a pre-clinical stage asset from our acquisition of Bamboo for gene therapies for the potential treatment of patients with certain rare diseases, which was the result of a determination to not use certain Bamboo IPR&D acquired in future rare disease development and (ii) $40 million related to a Biopharma developed technology right, acquired in connection with our acquisition of King, for government defense products and reflects, among other things, updated commercial forecasts including manufacturing cost assumptions. In addition, the first quarter of 2019 included other asset impairments of $20 million . (f) In the first quarter of 2019, represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services. (g) See Note 2B for additional information. (h) The first quarter of 2020 includes, among other things, dividend income of $77 million from our investment in ViiV. The first quarter of 2019 included, among other things, credits of $72 million , reflecting the change in the fair value of contingent consideration, and dividend income of $64 million from our investment in ViiV.

Tax Matters

Tax Matters	3 Months Ended
	Mar. 29, 2020
Income Tax Disclosure [Abstract]
Tax Matters	Tax Matters A. Taxes on Income from Continuing Operations Our effective tax rate for continuing operations was 12.2% for the first quarter of 2020 , compared to 10.0% for the first quarter of 2019 . The higher effective tax rate for the first quarter of 2020 in comparison with the same period in 2019 was primarily due to: • the non-recurrence of the tax benefit recorded in the first quarter of 2019 as a result of additional guidance issued by the U.S. Department of Treasury related to the TCJA; and • a decrease in tax benefits associated with the resolution of certain tax positions pertaining to prior years, partially offset by: • the favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business. Our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings for which we elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight years through 2026 is reported in current Income taxes payable (approximately $650 million ) and the remaining liability is reported in noncurrent Other taxes payable in our condensed consolidated balance sheet as of March 29, 2020 . We expect to pay the second installment of $650 million in July 2020, which was originally due to be paid in April 2020 but was recently extended to July 2020 by the IRS in response to the COVID-19 pandemic. Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was signed into law in the U.S. to provide certain relief as a result of the COVID-19 pandemic. In addition, governments around the world have enacted or implemented various forms of tax relief measures in response to the economic conditions in the wake of COVID-19. As of March 29, 2020, neither the CARES Act nor changes to income tax laws or regulations in other jurisdictions had a significant impact on our effective tax rate. B. Tax Contingencies We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. With respect to Pfizer, tax years 2011-2015 are currently under audit. Tax years 2016-2020 are open, but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years in other major tax jurisdictions, such as Canada (2013-2020), Japan (2017-2020), Europe (2011-2020, primarily reflecting Ireland, the U.K., France, Italy, Spain and Germany), Latin America (1998-2020, primarily reflecting Brazil) and Puerto Rico (2015-2020). C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss) The following table provides the components of Tax provision/(benefit) on other comprehensive income/(loss) : Three Months Ended (MILLIONS OF DOLLARS) March 29, March 31, Foreign currency translation adjustments, net (a) $ (252 ) $ 27 Unrealized holding gains/(losses) on derivative financial instruments, net (133 ) 59 Reclassification adjustments for (gains)/losses included in net income 15 (55 ) (118 ) 4 Unrealized holding gains/(losses) on available-for-sale securities, net (6 ) 5 Reclassification adjustments for losses included in net income 2 1 (5 ) 7 Benefit plans: actuarial losses, net (21 ) — Reclassification adjustments related to amortization 15 3 Reclassification adjustments related to settlements, net 9 — Other 4 (5 ) 8 (2 ) Reclassification adjustments related to amortization of prior service costs and other, net (11 ) (11 ) Other — — (11 ) (11 ) Tax provision/(benefit) on other comprehensive income/(loss) $ (377 ) $ 25 (a) Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests	3 Months Ended
	Mar. 29, 2020
Equity [Abstract]
Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests	Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests The following table provides the changes, net of tax, in Accumulated other comprehensive loss : Net Unrealized Gains/(Losses) Benefit Plans (MILLIONS OF DOLLARS) Foreign Currency Translation Adjustments Derivative Financial Instruments Available-For-Sale Securities Actuarial Gains/(Losses) Prior Service (Costs)/Credits and Other Accumulated Other Comprehensive Income/(Loss) Balance, December 31, 2019 $ (5,952 ) $ 20 $ (35 ) $ (6,257 ) $ 584 $ (11,640 ) Other comprehensive income/(loss) (a) (1,020 ) (364 ) (32 ) (39 ) (35 ) (1,490 ) Balance, March 29, 2020 $ (6,973 ) $ (344 ) $ (67 ) $ (6,296 ) $ 549 $ (13,131 ) (a) Includes after-tax losses of approximately $1.2 billion related to foreign currency translation adjustments attributable to our equity method investment in GSK Consumer Healthcare (see Note 2B ), partially offset by the results of our net investment hedging program. As of March 29, 2020 , with respect to derivative financial instruments, the amount of unrealized pre-tax net gains on derivative financial instruments, which are included in Accumulated Other Comprehensive Loss , estimated to be reclassified into income within the next 12 months is approximately $294 million . The net gains are expected to be offset primarily by net losses from foreign currency exchange-denominated forecasted intercompany inventory sales upon the sale of the inventory to a third party.

Financial Instruments

Financial Instruments	3 Months Ended
	Mar. 29, 2020
Financial Instruments [Abstract]
Financial Instruments	Financial Instruments A. Fair Value Measurements Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis The following table presents the financial assets and liabilities measured at fair value using a market approach on a recurring basis by balance sheet categories and fair value hierarchy level as defined in Notes to Consolidated Financial Statements–– Note 1E. Basis of Presentation and Significant Accounting Policies: Fair Value in our 2019 Financial Report: March 29, 2020 December 31, 2019 (MILLIONS OF DOLLARS) Total Level 1 Level 2 Total Level 1 Level 2 Financial assets measured at fair value on a recurring basis: Short-term investments Classified as equity securities with readily determinable fair values: Money market funds $ 4,190 $ — $ 4,190 $ 705 $ — $ 705 Classified as available-for-sale debt securities: Government and agency—non-U.S. 1,989 — 1,989 4,863 — 4,863 Government and agency—U.S. 16 — 16 811 — 811 Corporate and other 806 — 806 1,013 — 1,013 2,812 — 2,812 6,687 — 6,687 Total short-term investments 7,002 — 7,002 7,392 — 7,392 Other current assets Derivative assets: Interest rate contracts 15 — 15 53 — 53 Foreign exchange contracts 688 — 688 413 — 413 Total other current assets 702 — 702 465 — 465 Long-term investments Classified as equity securities with readily determinable fair values (a) 1,603 1,581 22 1,902 1,863 39 Classified as available-for-sale debt securities: Government and agency—U.S. 285 — 285 303 — 303 Corporate and other 11 — 11 11 — 11 296 — 296 315 — 315 Total long-term investments 1,899 1,581 318 2,216 1,863 354 Other noncurrent assets Derivative assets: Interest rate contracts 134 — 134 266 — 266 Foreign exchange contracts 356 — 356 261 — 261 Total derivative assets 490 — 490 526 — 526 Insurance contracts (b) 530 — 530 575 — 575 Total other noncurrent assets 1,020 — 1,020 1,102 — 1,102 Total assets $ 10,623 $ 1,581 $ 9,042 $ 11,176 $ 1,863 $ 9,313 Financial liabilities measured at fair value on a recurring basis: Other current liabilities Derivative liabilities: Foreign exchange contracts $ 109 $ — $ 109 $ 114 $ — $ 114 Total other current liabilities 109 — 109 114 — 114 Other noncurrent liabilities Derivative liabilities: Foreign exchange contracts 1,139 — 1,139 604 — 604 Total other noncurrent liabilities 1,139 — 1,139 604 — 604 Total liabilities $ 1,248 $ — $ 1,248 $ 718 $ — $ 718 (a) As of March 29, 2020 , long-term equity securities of $155 million and as of December 31, 2019 , long-term equity securities of $176 million were held in restricted trusts for benefits attributable to various U.S. non-qualified employee benefit plans. (b) Other noncurrent assets include life insurance policies held in restricted trusts attributable to the funding of various U.S. non-qualified employee benefit plans. The underlying invested assets in these insurance contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions –– net in the consolidated statements of income (see Note 4 ). Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis The following table presents the financial liabilities not measured at fair value on a recurring basis, including the carrying values and estimated fair values using a market approach: March 29, 2020 December 31, 2019 Carrying Value Estimated Fair Value Carrying Value Estimated Fair Value (MILLIONS OF DOLLARS) Total Level 2 Total Level 2 Financial Liabilities Long-term debt, excluding the current portion $ 36,281 $ 40,062 $ 40,062 $ 35,955 $ 40,842 $ 40,842 The differences between the estimated fair values and carrying values of held-to-maturity debt securities, restricted stock and private equity securities, and short-term borrowings not measured at fair value on a recurring basis were not significant as of March 29, 2020 or December 31, 2019 . The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs. The fair value measurements of our private equity securities, which represent investments in the life sciences sector, are based on Level 3 inputs using a market approach. In addition, as of March 29, 2020 and December 31, 2019 , we had long-term receivables whose fair value is based on Level 3 inputs. As of March 29, 2020 and December 31, 2019 , the differences between the estimated fair values and carrying values of these receivables were not significant. Total Short-Term and Long-Term Investments and Equity-Method Investments The following table represents our investments by classification type: (MILLIONS OF DOLLARS) March 29, December 31, Short-term investments Equity securities with readily determinable fair values (a) $ 4,190 $ 705 Available-for-sale debt securities 2,812 6,687 Held-to-maturity debt securities 1,198 1,133 Total Short-term investments $ 8,199 $ 8,525 Long-term investments Equity securities with readily determinable fair values $ 1,603 $ 1,902 Available-for-sale debt securities 296 315 Held-to-maturity debt securities 40 42 Private equity securities at cost 757 756 Total Long-term investments $ 2,696 $ 3,014 Equity-method investments 15,524 17,133 Total long-term investments and equity-method investments $ 18,220 $ 20,147 Held-to-maturity cash equivalents $ 401 $ 163 (a) As of March 29, 2020 and December 31, 2019 , equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt. B. Investments Debt Securities At March 29, 2020, our investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt securities at March 29, 2020 and December 31, 2019 is as follows, including, as of March 29, 2020, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities: March 29, 2020 December 31, 2019 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS OF DOLLARS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 Over 5 Total Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency –– non-U.S. $ 2,056 $ — $ (67 ) $ 1,989 $ 1,989 $ — $ — $ 1,989 $ 4,895 $ 6 $ (38 ) $ 4,863 Government and agency––U.S. 305 — (4 ) 302 16 285 — 302 1,120 — (6 ) 1,114 Corporate and other (a) 823 — (6 ) 817 807 11 — 817 1,027 — (2 ) 1,025 Held-to-maturity debt securities Time deposits and other 624 — — 624 589 8 28 624 535 — — 535 Government and agency –– non-U.S. 1,014 — — 1,014 1,010 — 4 1,014 803 — — 803 Total debt securities $ 4,823 $ 1 $ (77 ) $ 4,746 $ 4,410 $ 304 $ 32 $ 4,746 $ 8,380 $ 6 $ (47 ) $ 8,340 (a) Primarily issued by a diverse group of corporations. For our portfolio of available-for-sale and held-to-maturity debt securities, any expected credit losses would be immaterial to the financial statements. Equity Securities The following table presents the net unrealized (gains) and losses for the period that relate to equity securities, excluding equity method investments, still held at the reporting date, calculated as follows: Three Months Ended (MILLIONS OF DOLLARS) March 29, March 31, Net (gains)/losses recognized during the period on equity securities (a ) $ 255 $ (111 ) Less: Net gains recognized during the period on equity securities sold during the period (19 ) (5 ) Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date (b) $ 274 $ (106 ) (a) The net gains on investments in equity securities are reported in Other (income)/deductions –– net. For additional information, see Note 4 . (b) Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of $58 million and upward adjustments of $60 million . Impairments, downward and upward adjustments were not significant in the first quarter of 2020 and 2019 . C. Short-Term Borrowings Short-term borrowings include: (MILLIONS OF DOLLARS) March 29, December 31, Commercial paper $ 14,908 $ 13,915 Current portion of long-term debt, principal amount 334 1,458 Other short-term borrowings, principal amount (a) 800 860 Total short-term borrowings, principal amount 16,042 16,233 Net fair value adjustments related to hedging and purchase accounting 3 5 Net unamortized discounts, premiums and debt issuance costs (38 ) (43 ) Total Short-term borrowings, including current portion of long-term debt , carried at historical proceeds, as adjusted $ 16,007 $ 16,195 (a) Other short-term borrowings primarily include cash collateral. For additional information, see Note 7E D. Long-Term Debt New Issuance In the first quarter of 2020, we issued the following senior unsecured notes: (MILLIONS OF DOLLARS) Principal Interest Rate Maturity Date As of March 29, 2020 2.625% notes (a) April 1, 2030 $ 1,250 Total long-term debt issued in the first quarter of 2020 (b) $ 1,250 (a) Fixed rate notes may be redeemed by us at any time, in whole, or in part, at a redemption price plus accrued and unpaid interest. (b) The effective interest rate for the notes at issuance was 2.67% . The following table provides the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt: (MILLIONS OF DOLLARS) March 29, December 31, Total long-term debt, principal amount $ 34,778 $ 34,820 Net fair value adjustments related to hedging and purchase accounting 1,671 1,305 Net unamortized discounts, premiums and debt issuance costs (173 ) (176 ) Other long-term debt 5 5 Total long-term debt, carried at historical proceeds, as adjusted $ 36,281 $ 35,955 Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above) $ 337 $ 1,462 Retirements In March 2020, we repurchased all $1.065 billion principal amount outstanding of our senior unsecured notes that were due 2047 before the maturity date at par, which did not have a material impact on our condensed consolidated financial statements. E. Derivative Financial Instruments and Hedging Activities Foreign Exchange Risk A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. We manage our foreign exchange risk, in part, through operational means, including managing same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. We also manage our foreign exchange risk, depending on market conditions, through fair value, cash flow, and net investment hedging programs through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to protect net income against the impact of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions. The derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, Japanese yen, Chinese renminbi and Swedish krona . As a part of our cash flow hedging program, we designate foreign exchange contracts to hedge a portion of our forecasted euro, Japanese yen, Chinese renminbi, Canadian dollar, U.K. pound and Australian dollar -denominated intercompany inventory sales expected to occur no more than two years from the date of each hedge. Interest Rate Risk Our interest-bearing investments and borrowings are subject to interest rate risk. With respect to our investments, we strive to maintain a predominantly floating-rate basis position, but our strategy may change based on prevailing market conditions. We currently borrow primarily on a long-term, fixed-rate basis. From time to time, depending on market conditions, we will change the profile of our outstanding debt by entering into derivative financial instruments like interest rate swaps. We entered into derivative financial instruments to hedge or offset the fixed interest rates on the hedged item, matching the amount and timing of the hedged item. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt. The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments: (MILLIONS OF DOLLARS) March 29, 2020 December 31, 2019 Fair Value Fair Value Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments: Foreign exchange contracts (a) $ 23,877 $ 955 $ 1,150 $ 25,193 $ 591 $ 662 Interest rate contracts 1,995 148 — 6,645 318 — 1,103 1,150 909 662 Derivatives not designated as hedging instruments: Foreign exchange contracts $ 13,402 89 97 $ 19,623 82 55 Total $ 1,192 $ 1,248 $ 992 $ 718 (a) The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $5.3 billion as of March 29, 2020 and $5.9 billion as of December 31, 2019. The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk: Amount of (a) Amount of Gains/(Losses) (a) , (b) Amount of Gains/(Losses) (a), (b) (MILLIONS OF DOLLARS) March 29, March 31, March 29, March 31, March 29, March 31, Three Months Ended Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign exchange contracts (c) $ — $ — $ (529 ) $ 210 $ (46 ) $ 209 Amount excluded from effectiveness testing recognized in earnings based on an amortization approach (d) — — 29 56 27 54 Derivative Financial Instruments in Fair Value Hedge Relationships: Interest rate contracts 386 329 — — — — Hedged item (386 ) (329 ) — — — — Foreign exchange contracts — — — — — — Hedged item — — — — — — Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign exchange contracts — — 384 23 — — The portion on foreign exchange contracts excluded from the assessment of hedge effectiveness (d) — — 147 41 41 24 Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency short-term borrowings (e) — — 8 35 — — Foreign currency long-term debt (e) — — 45 38 — — Derivative Financial Instruments Not Designated as Hedges: Foreign exchange contracts (59 ) (120 ) — — — — All other net (d) — — (1 ) 1 — — $ (59 ) $ (120 ) $ 83 $ 404 $ 23 $ 286 (a) OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of income . COS = Cost of Sales, included in Cost of sales in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income . (b) For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in Other comprehensive income/(loss)––Unrealized holding gains/(losses) on derivative financial instruments, net . For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the gains and losses are included in Other comprehensive income/(loss)––Foreign currency translation adjustments, net. (c) The amounts reclassified from OCI into COS were a net gain of $70 million in the first quarter of 2020 and a net gain of $44 million in the first quarter of 2019. The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $220 million within the next 12 months into Cost of sales. The maximum length of time over which we are hedging future foreign exchange cash flow relates to our $1.8 billion U.K. pound debt maturing in 2043. (d) The amounts reclassified from OCI were reclassified into OID. (e) Long-term debt includes foreign currency long-term borrowings with carrying values of $1.9 billion as of March 29, 2020 , which are used as hedging instruments in net investment hedges. The following table provides the amounts recorded in our condensed consolidated balance sheet related to cumulative basis adjustments for fair value hedges: March 29, 2020 December 31, 2019 Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount (MILLIONS OF DOLLARS) Carrying Amount of Hedged Assets/Liabilities (a) Active Hedging Relationships Discontinued Hedging Relationships Carrying Amount of Hedged Assets/Liabilities (a) Active Hedging Relationships Discontinued Hedging Relationships Long-term investments $ 45 $ — $ — $ 45 $ — $ — Long-term debt 2,027 134 1,196 7,092 266 690 (a) Carrying amounts exclude the cumulative amount of fair value hedging adjustments. Certain of our derivative financial instruments are covered by associated credit-support agreements that have credit-risk-related contingent features designed to reduce both counterparties’ exposure to risk of defaulting on amounts owed by the other party. As of March 29, 2020 , the aggregate fair value of these derivative financial instruments that are in a net liability position was $1.1 billion , which is fully collateralized. As of February 23, 2020 , our fiscal quarter-end for subsidiaries operating outside the U.S., we have posted $463 million in collateral. If there had been a downgrade to below an A rating by S&P or the equivalent rating by Moody’s, we would not have been required to post any additional collateral to our counterparties. As of March 29, 2020 , we received cash collateral of $791 million from various counterparties. The collateral primarily supports the approximate fair value of our derivative contracts. With respect to the collateral received, the obligations are reported in Short-term borrowings, including current portion of long-term debt. F. Credit Risk On an ongoing basis, we review the creditworthiness of counterparties to our foreign exchange and interest rate agreements and do not expect to incur a significant loss from failure of any counterparties to perform under the agreements. There are no significant concentrations of credit risk related to our financial instruments with any individual counterparty. For additional information about concentrations of certain credit risk related to certain significant customers, see Notes to Consolidated Financial Statements–– Note 17C. Segment, Geographic and Other Revenue Information: Other Revenue Information in Pfizer’s 2019 Financial Report. As of March 29, 2020 , we had amounts due from a well-diversified, high quality group of banks ( $1.3 billion ) from around the world. For details about our investments, see Note 7B above . In general, there is no requirement for collateral from customers. However, derivative financial instruments are executed under credit-support agreements that provide for the ability to request to receive cash collateral, depending on levels of exposure, our credit rating and the credit rating of the counterparty, see Note 7E above.

Inventories

Inventories	3 Months Ended
	Mar. 29, 2020
Inventory Disclosure [Abstract]
Inventories	Inventories The following table provides the components of Inventories : (MILLIONS OF DOLLARS) March 29, December 31, Finished goods $ 2,703 $ 2,750 Work-in-process 4,962 4,743 Raw materials and supplies 757 790 Inventories (a) $ 8,423 $ 8,283 Noncurrent inventories not included above (b) $ 720 $ 714 (a) The change from December 31, 2019 reflects increases for certain products, including inventory build for new product launches, market demand and network strategy, partially offset by a decrease due to foreign exchange. (b) Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.

Identifiable Intangible Assets

Identifiable Intangible Assets and Goodwill	3 Months Ended
	Mar. 29, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Identifiable Intangible Assets and Goodwill	Identifiable Intangible Assets and Goodwill A. Identifiable Intangible Assets Balance Sheet Information The following table provides the components of Identifiable intangible assets : March 29, 2020 December 31, 2019 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights $ 88,519 $ (63,783 ) $ 24,736 $ 88,730 $ (63,106 ) $ 25,625 Brands 922 (749 ) 173 922 (741 ) 181 Licensing agreements and other 1,779 (1,206 ) 574 1,772 (1,191 ) 582 91,221 (65,738 ) 25,482 91,425 (65,037 ) 26,387 Indefinite-lived intangible assets Brands 1,991 1,991 1,991 1,991 IPR&D (a) 5,918 5,918 5,919 5,919 Licensing agreements and other 1,073 1,073 1,073 1,073 8,982 8,982 8,983 8,983 Identifiable intangible assets (a) $ 100,203 $ (65,738 ) $ 34,464 $ 100,408 $ (65,037 ) $ 35,370 (a) The decrease in I dentifiable intangible assets, less accumulated amortization , is primarily due to amortization. Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization: March 29, 2020 Biopharma Upjohn WRDM Developed technology rights 99 % 1 % — Brands, finite-lived 100 % — — Brands, indefinite-lived 42 % 58 % — IPR&D 95 % — 5 % Licensing agreements and other, finite-lived 97 % 1 % 1 % Licensing agreements and other, indefinite-lived 100 % — — Amortization Total amortization expense for finite-lived intangible assets was $897 million for the first quarter of 2020 and $1.2 billion for the first quarter of 2019 . B. Goodwill The following table provides the components of and changes in the carrying amount of Goodwill : (MILLIONS OF DOLLARS) Biopharma Upjohn Total Balance, December 31, 2019 $ 48,202 $ 10,451 $ 58,653 Other (a) (122 ) (30 ) (151 ) Balance, March 29, 2020 $ 48,081 $ 10,421 $ 58,502 (a) Represents the impact of foreign exchange.

Pension and Postretirement Bene

Pension and Postretirement Benefit Plans	3 Months Ended
	Mar. 29, 2020
Retirement Benefits [Abstract]
Pension and Postretirement Benefit Plans	Pension and Postretirement Benefit Plans The following table provides the components of net periodic benefit cost/(credit): Three Months Ended Pension Plans U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans (MILLIONS OF DOLLARS) March 29, March 31, March 29, March 31, March 29, March 31, March 29, March 31, Service cost $ — $ — $ — $ — $ 36 $ 32 $ 10 $ 9 Interest cost 131 157 10 12 42 54 13 19 Expected return on plan assets (252 ) (223 ) — — (78 ) (80 ) (9 ) (8 ) Amortization of: Actuarial losses 32 37 4 2 31 20 — 1 Prior service credits (1 ) (1 ) — — (1 ) (1 ) (43 ) (45 ) Settlements 14 1 38 — 1 — — — Special termination benefits — — 1 6 — — — — $ (76 ) $ (28 ) $ 52 $ 20 $ 32 $ 25 $ (30 ) $ (23 ) The following table provides the amounts we contributed, and the amounts we expect to contribute during 2020, to our pension and postretirement plans from our general assets for the periods indicated: Pension Plans (MILLIONS OF DOLLARS) U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans Contributions from our general assets for the three months ended March 29, 2020 $ 3 $ 132 $ 46 $ 45 Expected contributions from our general assets during 2020 (a) 1,276 228 186 155 (a) Contributions expected to be made for 2020 are inclusive of amounts contributed during the three months ended March 29, 2020 . The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments. For the U.S. qualified plans, we plan to make a $1.25 billion voluntary contribution in the second half of 2020.

Earnings Per Common Share Attri

Earnings Per Common Share Attributable to Common Shareholders	3 Months Ended
	Mar. 29, 2020
Earnings Per Share [Abstract]
Earnings Per Common Share Attributable to Common Shareholders	Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders The following table provides the detailed calculation of EPS : Three Months Ended (IN MILLIONS) March 29, March 31, EPS Numerator––Basic Income from continuing operations $ 3,410 $ 3,889 Less: Net income attributable to noncontrolling interests 9 6 Income from continuing operations attributable to Pfizer Inc. 3,401 3,884 Less: Preferred stock dividends––net of tax — — Income from continuing operations attributable to Pfizer Inc. common shareholders 3,401 3,883 Discontinued operations––net of tax — — Net income attributable to Pfizer Inc. common shareholders $ 3,401 $ 3,883 EPS Numerator––Diluted Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions $ 3,401 $ 3,884 Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions — — Net income attributable to Pfizer Inc. common shareholders and assumed conversions $ 3,401 $ 3,884 EPS Denominator Weighted-average number of common shares outstanding––Basic 5,545 5,635 Common-share equivalents: stock options, stock issuable under employee compensation plans and convertible preferred stock 68 115 Weighted-average number of common shares outstanding––Diluted 5,613 5,750 Anti-dilutive common stock equivalents (a) 3 2 (a) These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect. In December 2019, our Board of Directors declared a first-quarter 2020 dividend of $0.38 per share, payable on March 6, 2020, to shareholders of record at the close of business on January 31, 2020. In December 2018, our Board of Directors declared a first-quarter 2019 dividend of $0.36 per share, payable on March 1, 2019, to shareholders of record at the close of business on February 1, 2019.

Contingencies and Certain Commi

Contingencies and Certain Commitments	3 Months Ended
	Mar. 29, 2020
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Certain Commitments	Contingencies and Certain Commitments We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies. For a discussion of our tax contingencies, see Note 5B. For a discussion of our legal contingencies, see below. A. Legal Proceedings Our legal contingencies include, but are not limited to, the following: • Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. We are the plaintiff in the majority of these actions. An adverse outcome in actions in which we are the plaintiff could result in loss of patent protection for a drug, a significant loss of revenues from that drug or impairment of the value of associated assets. • Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters. • Commercial and other matters, which can include merger-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter. • Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions. Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, which could be substantial, and/or criminal charges. We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the period in which the amounts are paid. We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. As a result of considering qualitative factors in our determination of principal matters, there are some matters discussed below with respect to which management believes that the likelihood of possible loss in excess of amounts accrued is remote. A1. Legal Proceedings––Patent Litigation Like other pharmaceutical companies, we are involved in numerous suits relating to our patents, including but not limited to, those discussed below. Most of the suits involve claims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents on a number of our products that are discussed below, patent rights to certain of our products are being challenged in various other jurisdictions. We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. Additionally, our licensing and collaboration partners face challenges by generic drug manufacturers to patents covering products for which we have licenses or co-promotion rights. We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the U.S. In October 2017, the Patent Trial and Appeal Board (PTAB) refused to initiate proceedings as to two patents. In June 2018, the PTAB ruled on another patent, holding that one claim was valid and that all other claims were invalid. The party challenging that patent appealed the decision. In November 2019, the U.S. Court of Appeals for the Federal Circuit vacated the PTAB’s ruling and requested that the PTAB redecide the challenge. In March and June 2019, an additional patent was found invalid in separate proceedings by the PTAB. We appealed. In January 2020, the U.S. Court of Appeals for the Federal Circuit vacated the original decision and requested that the PTAB redecide the case. Challenges to other patents remain pending in jurisdictions outside the U.S. The invalidation of all of the patents in our pneumococcal portfolio could potentially allow a competitor pneumococcal vaccine into the marketplace. In the event that any of the patents are found valid and infringed, a competitor pneumococcal vaccine might be prohibited from entering the market or required to pay Pfizer a royalty. We are also subject to patent litigation pursuant to which one or more third parties seek damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our Hospira subsidiaries are involved in patent and patent-related disputes over their attempts to bring generic pharmaceutical and biosimilar products to market. If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold in the event that we or one of our subsidiaries, like Hospira, is found to have willfully infringed valid patent rights of a third party. Actions In Which We Are The Plaintiff EpiPen In July 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for the District of New Jersey in connection with Sandoz’s abbreviated new drug application filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name. Precedex Premix Beginning in 2014, several generic manufacturers filed separate abbreviated new drug applications with the FDA, seeking approval to market their generic versions of our subsidiary Hospira’s premix version of Precedex prior to the expiration of one or more patents covering the product. One of those patents expired in March 2019, while others do not expire until 2032. In response, beginning in 2014, Hospira brought suit against these generic manufacturers, in some cases joined by Orion Corporation (co-owner of certain of our Precedex premix patents). To date, two of the actions have been settled or dismissed on terms not material to Pfizer: (i) the action filed against Ben Venue Laboratories, Inc., which was sued along with Hikma Pharmaceuticals PLC (together, succeeded by Eurohealth International Sarl) and West-Ward Pharmaceuticals Corp (collectively, the Ben Venue case); and (ii) the action filed against Baxter Healthcare Corporation. The remaining actions have concluded as described below. In August 2015, Hospira filed suit against Amneal Pharmaceuticals LLC (Amneal) in the U.S. District Court for the District of Delaware asserting the validity and infringement of four patents relating to the Precedex premix formulations and their use, all of which expire in 2032. In January 2018, the District Court ruled that one of the four patents was valid and infringed, and that the other three patents were invalid. The District Court also enjoined Amneal from marketing its proposed generic product. Amneal and Hospira appealed the District Court decision and in January 2019, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court’s decision. In March 2020, following the U.S. Court of Appeals for the Federal Circuit decision in the Fresenius case below, the District Court entered an order ending the injunction against Amneal. In December 2015, Fresenius Kabi USA LLC (Fresenius) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that certain patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In January 2016, Hospira filed suit against Fresenius in the U.S. District Court for the Northern District of Illinois, asserting the validity and infringement of those patents. In December 2018, the District Court ruled that the asserted claims of two patents were invalid. Hospira appealed the District Court’s decision as to one of the patents to the U.S. Court of Appeals for the Federal Circuit. In January 2020, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court’s decision. Separate actions in which Hospira sued Par Sterile Products LLC, Gland Pharma Limited, and Jiangsu Hengrui Medicine Co., Ltd., each in response to such generic manufacturer’s filing of a separate abbreviated new drug application with the FDA seeking approval to market their generic versions of our subsidiary Hospira’s premix version of Precedex prior to the expiration of one or more patents covering the product, were stayed pending the outcome of the case against Fresenius described above. In March 2020, following the U.S. Court of Appeals for the Federal Circuit decision in the Fresenius case above, all three cases were dismissed. Xeljanz (tofacitinib) Beginning in 2017, we brought patent-infringement actions against several generic manufacturers that filed separate abbreviated new drug applications with the FDA seeking approval to market their generic versions of tofacitinib tablets in one or both of 5 mg and 10 mg dosage strengths, and in both immediate and extended release forms. To date, actions against the following generic manufacturers have been settled on terms not material to Pfizer: (i) MicroLabs USA Inc. and MicroLabs Ltd.; (ii) Sun Pharmaceutical Industries Ltd.; (iii) Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., Huahai US Inc. and Solco Healthcare US, LLC; and (iv) Breckenridge Pharmaceutical Inc., Pensa Pharma S.A. and Laboratorios Del Dr. Esteve, S.A. The remaining actions continue as described below. In March 2017, we brought a patent-infringement action against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus) in the U.S. District Court for the District of Delaware asserting the infringement and validity of three patents: the patent covering the active ingredient expiring in December 2025, the patent covering an enantiomer of tofacitinib expiring in 2022, and the patent covering a polymorphic form of tofacitinib expiring in 2023, which Zydus challenged in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets. In December 2018, we brought a separate patent infringement action against Teva Pharmaceuticals USA, Inc. (Teva) in the U.S. District Court for the District of Delaware asserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Teva in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 11 mg extended release tablets. In March 2019, we brought a separate patent infringement action against Ajanta Pharma Ltd. and Ajanta Pharma USA Inc. (collectively, Ajanta) in the U.S. District Court for the District of Delaware asserting the infringement and validity of two patents: the patent covering the active ingredient that expires in December 2025 and the patent covering a polymorphic form of tofacitinib that expires in 2023, each of which Ajanta challenged in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets. In August 2019, in response to a similar challenge by Ajanta relating the tofacitinib 10 mg tablets, we brought another patent infringement action against Ajanta in the U.S. District Court for the District of Delaware. Inlyta (axitinib) In April 2018, Apotex Inc. notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Inlyta. Apotex Inc. asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In May 2018, we filed suit against Apotex Inc. in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta. In May 2019, Glenmark Pharmaceuticals Limited (Glenmark) notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Inlyta. Glenmark asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In June 2019, we filed suit against Glenmark in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta. Kerydin (tavaborole) In September 2018, several generic companies notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Kerydin. The generic companies assert the invalidity and non-infringement of methods of use and formulation patents for tavaborole that expire in 2026 and 2027, including pediatric exclusivity. In October 2018, Anacor, our wholly-owned subsidiary , filed infringement lawsuits against each of the generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia. Ibrance (palbociclib) In March 2019, several generic companies notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Ibrance. The generic companies assert the invalidity and non-infringement of two composition of matter patents and a method of use patent covering palbociclib, each of which expire in 2023. In April 2019, we brought patent infringement actions against each of the generic filers in various federal courts, asserting the validity and infringement of the patents challenged by the generic companies. Chantix (varenicline) In January 2020, we brought a patent infringement action against Viwit Pharmaceutical Co. Ltd. (Viwit) in the U.S. District Court for the District of Delaware asserting the validity and infringement of three patents challenged by Viwit in its abbreviated new drug application seeking approval to market a generic version of varenicline, 0.5 mg and 1.0 mg tablets. Matter Involving Our Collaboration/Licensing Partners Eliquis In February, March, and April 2017, twenty-five generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed abbreviated new drug applications seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the three patents listed in the Orange Book for Eliquis. One of the patents expired in December 2019 and the remaining patents currently are set to expire in 2026 and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. In April 2017, BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia, asserting that each of the generic companies’ proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all three patents. We and BMS have settled with certain of the generic companies on terms not material to Pfizer, and we and BMS may settle with other generic companies in the future. Action In Which We Are The Defendant Inflectra (infliximab-dyyb) In March 2015, Janssen and New York University, together, brought a patent-infringement action in the U.S. District Court for the District of Massachusetts against Hospira, Celltrion Healthcare Co. Ltd. and Celltrion Inc. alleging that infliximab-dyyb, to be marketed by Hospira in the U.S. under the brand name Inflectra, would infringe six patents relating to infliximab, its manufacture and use. Claims with respect to four of the patents were dismissed by the plaintiffs, leaving two patents at issue: the infliximab antibody patent and a patent relating to cell culture media. In January 2018, the antibody patent was declared invalid by the Court of Appeals for the Federal Circuit. In July 2018, the U.S. District Court for the District of Massachusetts granted defendants’ motion for summary judgment and ruled that the patent relating to cell culture media was not infringed. Janssen appealed the District Court’s decision to the U.S. Court of Appeals for the Federal Circuit. In March 2020, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court’s decision. A2. Legal Proceedings––Product Litigation Like other pharmaceutical companies, we are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. Asbestos Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. Claims against American Optical and numerous other defendants are pending in various federal and state courts seeking damages for alleged personal injury from exposure to asbestos and other allegedly hazardous materials. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims. Numerous lawsuits are pending against Pfizer in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries. There also are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries. Effexor Beginning in May 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants’ allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. In October 2014, the District Court dismissed the direct purchaser plaintiffs’ claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In January 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court’s decisions and remanded the claims to the District Court. Lipitor • Antitrust Actions Beginning in November 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain affiliates of Pfizer, and, in most of the actions, Ranbaxy, Inc. (Ranbaxy) and certain affiliates of Ranbaxy. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants’ allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor, and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation ( In re Lipitor Antitrust Litigation MDL-2332 ) in the U.S. District Court for the District of New Jersey. In September 2013 and 2014, the District Court dismissed with prejudice the claims by direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court’s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court’s decisions and remanded the claims to the District Court. Also, in January 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. • Personal Injury Actions A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed type 2 diabetes purportedly as a result of the ingestion of Lipitor. Plaintiffs seek compensatory and punitive damages. In February 2014, the federal actions were transferred for consolidated pre-trial proceedings to a Multi-District Litigation ( In re Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation (No. II) MDL-2502 ) in the U.S. District Court for the District of South Carolina. Since 2016, certain cases in the Multi-District Litigation were remanded to certain state courts. In January 2017, the District Court granted our motion for summary judgment, dismissing substantially all of the remaining cases pending in the Multi-District Litigation. In January 2017, the plaintiffs appealed the District Court’s decision to the U.S. Court of Appeals for the Fourth Circuit. In June 2018, the U.S. Court of Appeals for the Fourth Circuit affirmed the District Court’s decision. Viagra Since April 2016, a Multi-District Litigation has been pending in the U.S. District Court for the Northern District of California ( In Re: Viagra (Sildenafil Citrate) Products Liability Litigation, MDL-2691 ), in which plaintiffs allege that they developed melanoma and/or the exacerbation of melanoma purportedly as a result of the ingestion of Viagra. Additional cases filed against Lilly with respect to Cialis have also been consolidated in the Multi-District Litigation (In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation, MDL-2691 ). In January 2020, the District Court granted our and Lilly’s motion to exclude all of plaintiffs’ general causation opinions. As a result, in April 2020, the District Court entered summary judgment in favor of defendants and dismissed all of plaintiffs’ claims. Intravenous Solutions Beginning in November 2016, purported class actions were filed in the U.S. District Court for the Northern District of Illinois against Hospira, Hospira Worldwide, Inc. and certain other defendants relating to intravenous saline solution. Plaintiffs sought to represent a class consisting of all persons and entities in the U.S. who directly purchased intravenous saline solution sold by any of the defendants from January 1, 2013 until the time the defendants’ allegedly unlawful conduct ceased. Plaintiffs alleged that the defendants’ conduct restricted output and artificially fixed, raised, maintained and/or stabilized the prices of intravenous saline solution sold throughout the U.S. in violation of federal antitrust laws. Plaintiffs sought treble damages (for themselves and on behalf of the putative classes) and an injunction against defendants for alleged price overcharges for intravenous saline solution in the U.S. since January 1, 2013. All actions were consolidated in the U.S. District Court for the Northern District of Illinois. In July 2018, the District Court granted defendants’ motions to dismiss the consolidated amended complaint without prejudice. Plaintiffs filed a second amended complaint in September 2018. In April 2020, the District Court granted defendants’ motions to dismiss the second amended complaint, and dismissed plaintiffs’ claims with prejudice. On February 3, 2017, we completed the sale of our global infusion systems net assets, HIS, which includes intravenous saline solution, to ICU Medical. The litigation is the subject of cross-claims for indemnification by both Pfizer and ICU Medical under the purchase agreement. Hormone Therapy Consumer Class Action A certified consumer class action is pending against Wyeth in the U.S. District Court for the Southern District of California based on the alleged off-label marketing of its hormone therapy products. The case was originally filed in December 2003. The class consists of California consumers who purchased Wyeth’s hormone-replacement products between January 1995 and January 2003 and who do not seek personal injury damages therefrom. The class seeks compensatory and punitive damages, including a full refund of the purchase price. In March 2020, the parties reached an agreement, and obtained preliminary court approval, to resolve this matter for $200 million . EpiPen Beginning in February 2017, purported class actions were filed in various federal courts by indirect purchasers of EpiPen against Pfizer, and/or its affiliates King and Meridian, and/or various entities affiliated with Mylan, and Mylan Chief Executive Officer, Heather Bresch. The plaintiffs in these actions seek to represent U.S. nationwide classes comprising persons or entities who paid for any portion of the end-user purchase price of an EpiPen between 2009 until the cessation of the defendants’ allegedly unlawful conduct. In August 2017, a similar lawsuit brought in the U.S. District Court for the District of New Jersey on behalf of a purported class of direct purchaser plaintiffs against Pfizer, King, Meridian and Mylan was voluntarily dismissed without prejudice. In February 2020, a similar lawsuit was filed in the U.S. District Court for the District of Kansas against Pfizer, King, Meridian and the Mylan entities on behalf of a purported U.S. nationwide class of direct purchaser plaintiffs who purchased EpiPen devices directly from the defendants (the 2020 Lawsuit). Against Pfizer and/or its affiliates, plaintiffs in these actions generally allege that Pfizer’s and/or its affiliates’ settlement of patent litigation regarding EpiPen delay

Segment, Geographic and Other R

Segment, Geographic and Other Revenue Information	3 Months Ended
	Mar. 29, 2020
Segment Reporting [Abstract]
Segment, Geographic and Other Revenue Information	Segment, Geographic and Other Revenue Information A. Segment Information At the beginning of our fiscal year 2019, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of three distinct business segments: Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and through July 31, 2019 , Pfizer’s Consumer Healthcare business (Consumer Healthcare), each led by a single manager. Each operating segment has responsibility for its commercial activities. Upjohn is and through July 31, 2019 , Consumer Healthcare was responsible for its own R&D activities while Biopharma receives its R&D services from GPD and WRDM. These services include IPR&D projects for new investigational products and additional indications for in-line products. Each business has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation. Biopharma and Upjohn are the only reportable segments. Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan). As a result, revenues and expenses associated with Meridian and Mylan-Japan are reported in our Upjohn business beginning in the first quarter of 2020. In 2019, revenues and expenses from Meridian and Mylan-Japan were recorded in our Biopharma business. We have revised prior-period information (Revenues and Earnings, as defined by management) to conform to the current management structure. As described in Notes to Consolidated Financial Statements— Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation in our 2019 Financial Report, recent acquisitions and the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture have impacted our results of operations. For additional information on the GSK Consumer Healthcare joint venture, see Note 2. Operating Segments Some additional information about our Biopharma and Upjohn business segments follows: Pfizer Biopharmaceuticals Group Biopharma is a science-based innovative medicines business that includes six business units – Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. The Hospital unit commercializes our global portfolio of sterile injectable and anti-infective medicines and includes Pfizer’s contract manufacturing operation, Pfizer CentreOne. Each business unit is committed to delivering breakthroughs that change patients’ lives. Upjohn is a global, primarily off-patent branded and generic medicines business, which includes a portfolio of 20 globally recognized solid oral dose brands, as well as a U.S.-based generics platform, Greenstone. Select products include: - Prevnar 13/Prevenar 13 - Eliquis - Ibrance - Xeljanz - Enbrel (outside the U.S. and Canada) Chantix/Champix - Vyndaqel/Vyndamax - Xtandi - Sutent Select products include: - Lipitor - Lyrica - Celebrex - Viagra - Certain generic medicines Other Costs and Business Activities Certain pre-tax costs are not allocated to our operating segment results, such as costs associated with the following: • WRDM––the R&D and Medical expenses managed by our WRDM organization, which is generally responsible for research projects for our Biopharma portfolio until proof-of-concept is achieved and then for transitioning those projects to the GPD organization for possible clinical and commercial development. R&D spending may include upfront and milestone payments for intellectual property rights. The WRDM organization also has responsibility for certain science-based and other platform-services organizations, which provide end-to-end technical expertise and other services to the various R&D projects, as well as the Worldwide Medical and Safety group, which ensures that Pfizer provides all stakeholders––including patients, healthcare providers, pharmacists, payers and health authorities––with complete and up-to-date information on the risks and benefits associated with Pfizer products so that they can make appropriate decisions on how and when to use Pfizer’s medicines. • GPD––the costs associated with our GPD organization, which is generally responsible for clinical trials from WRDM in the Biopharma portfolio, including late stage portfolio spend. GPD also provides technical support and other services to Pfizer R&D projects. GPD is responsible for facilitating all regulatory submissions and interactions with regulatory agencies. • Other––the operating results of our Consumer Healthcare business, through July 31, 2019, and costs associated with other commercial activities not managed as part of Biopharma or Upjohn, including all strategy, business development, portfolio management and valuation capabilities, which previously had been reported in various parts of the organization. • Corporate and Other Unallocated––the costs associated with platform functions (such as worldwide technology, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance, and worldwide procurement), patient advocacy activities and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing (which include manufacturing variances associated with production) and commercial operations that are not directly assessed to an operating segment, as business unit (segment) management does not manage these costs. • Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and PP&E; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items (such as gains on the completion of joint venture transactions, restructuring charges, legal charges or gains and losses from equity securities) that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities. Segment Assets We manage our assets on a Total Company basis, not by operating segment, as many of our operating assets are shared or commingled (such as accounts receivable, as many of our customers are served by multiple operating segments). Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately $166 billion as of March 29, 2020 and $167 billion as of December 31, 2019 . Selected Income Statement Information The following table provides selected income statement information by reportable segment: Three Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) March 29, March 31, March 29, March 31, Reportable Segments: Biopharma $ 10,007 $ 9,045 $ 6,729 $ 5,883 Upjohn 2,022 3,214 1,191 2,279 Total reportable segments 12,028 12,259 7,920 8,162 Other business activities — 858 (1,489 ) (1,113 ) Reconciling Items: Corporate and other unallocated — — (1,110 ) (1,278 ) Purchase accounting adjustments — — (812 ) (1,038 ) Acquisition-related costs — — (13 ) (28 ) Certain significant items (b) — — (612 ) (382 ) $ 12,028 $ 13,118 $ 3,885 $ 4,323 (a) Income from continuing operations before provision for taxes on income . Biopharma’s earnings include d ividend income of $77 million in the first quarter of 2020 and $64 million in the first quarter of 2019 from our investment in ViiV. For additional information, see Note 4. (b) Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Equity in the net income of investees accounted for by the equity method is not significant for any of our operating segments. The operating segment information does not purport to represent the revenues, costs and Income from continuing operations before provision for taxes on income that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented. B. Geographic Information The following table provides revenues by geographic area: Three Months Ended (MILLIONS OF DOLLARS) March 29, March 31, % Change United States $ 5,651 $ 6,175 (8 ) Developed Europe (a) 1,921 2,086 (8 ) Developed Rest of World (b) 1,456 1,535 (5 ) Emerging Markets (c) 3,001 3,322 (10 ) Revenues $ 12,028 $ 13,118 (8 ) (a) Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.5 billion in the first quarter of 2020 and $1.7 billion in the first quarter of 2019 . (b) Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand. (c) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey. C. Other Revenue Information Significant Product Revenues The following table provides detailed revenue information for several of our major products: (MILLIONS OF DOLLARS) Three Months Ended PRODUCT PRIMARY INDICATION OR CLASS March 29, March 31, TOTAL REVENUES $ 12,028 $ 13,118 PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA) $ 10,007 $ 9,045 Internal Medicine (a) $ 2,332 $ 2,137 Eliquis alliance revenues and direct sales Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism 1,300 1,011 Chantix/Champix An aid to smoking cessation treatment in adults 18 years of age or older 270 273 Premarin family Symptoms of menopause 152 168 BMP2 Development of bone and cartilage 69 67 Toviaz Overactive bladder 60 60 All other Internal Medicine Various 480 559 Oncology $ 2,435 $ 1,961 Ibrance Metastatic breast cancer 1,248 1,133 Xtandi alliance revenues Non-metastatic and metastatic castration-resistant prostate cancer and non-metastatic castration-sensitive prostate cancer 209 168 Sutent Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor 205 232 Inlyta Advanced RCC 169 73 Xalkori ALK-positive and ROS1-positive advanced NSCLC 149 123 Bosulif Philadelphia chromosome–positive chronic myelogenous leukemia 100 80 Retacrit (b) Anemia 89 31 Braftovi In combination with Mektovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation and, in combination with Erbitux ® (cetuximab), for the treatment of BRAF V600E -mutant metastatic colorectal cancer after prior therapy 37 — Mektovi In combination with Braftovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation 37 — All other Oncology Various 192 122 Hospital (a), (c) $ 2,012 $ 1,827 Sulperazon Bacterial infections 187 177 Zithromax Bacterial infections 138 104 Medrol Anti-inflammatory glucocorticoid 129 120 Vfend Fungal infections 74 85 Panzyga Primary humoral immunodeficiency 74 17 Zyvox Bacterial infections 70 64 Fragmin Treatment/prevention of venous thromboembolism 59 60 Pfizer CentreOne (d) Various 152 176 All other Anti-infectives Various 444 405 All other Hospital (c) Various 684 620 Vaccines $ 1,611 $ 1,612 Prevnar 13/Prevenar 13 Pneumococcal disease 1,450 1,486 Nimenrix Meningococcal disease 75 50 All other Vaccines Various 86 77 Inflammation & Immunology (I&I) $ 978 $ 1,037 Xeljanz RA, PsA, UC 451 423 Enbrel (Outside the U.S. and Canada) RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis 347 451 Inflectra/Remsima (b) Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis 158 138 All other I&I Various 22 25 Rare Disease $ 639 $ 470 Vyndaqel/Vyndamax ATTR-cardiomyopathy and polyneuropathy 231 41 BeneFIX Hemophilia B 121 125 Genotropin Replacement of human growth hormone 103 107 Refacto AF/Xyntha Hemophilia A 89 106 Somavert Acromegaly 64 59 All other Rare Disease Various 31 31 (MILLIONS OF DOLLARS) Three Months Ended PRODUCT PRIMARY INDICATION OR CLASS March 29, March 31, UPJOHN (a) $ 2,022 $ 3,214 Lipitor Reduction of LDL cholesterol 405 622 Lyrica Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury 357 1,186 Norvasc Hypertension 197 300 Celebrex Arthritis pain and inflammation, acute pain 156 174 Viagra Erectile dysfunction 127 145 Zoloft Depression and certain anxiety disorders 78 69 Effexor Depression and certain anxiety disorders 77 77 EpiPen (a) Epinephrine injection used in treatment of life-threatening allergic reactions 72 56 Xalatan/Xalacom Glaucoma and ocular hypertension 61 62 All other Upjohn Various 492 523 CONSUMER HEALTHCARE BUSINESS (e) $ — $ 858 Total Alliance revenues Various $ 1,382 $ 1,090 Total Biosimilars (b) Various $ 288 $ 179 Total Sterile Injectable Pharmaceuticals (f) $ 1,407 $ 1,237 (a) Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan). As a result, revenues associated with our Meridian subsidiary, except for product revenues for EpiPen sold in Canada, and Mylan-Japan, are reported in our Upjohn business beginning in the first quarter of 2020. We have reclassified revenues associated with our Meridian subsidiary and Mylan-Japan from the Hospital and Internal Medicine categories to the Upjohn business to conform 2019 product revenues to the current presentation. (b) Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit. (c) Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. Hospital also includes Pfizer CentreOne (d) . All other Hospital primarily includes revenues from legacy Sterile Injectables Pharmaceuticals (SIP) products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in “All other Anti-infectives”. (d) Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements. (e) On July 31, 2019 , Pfizer’s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK’s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see Note 2B . (f) Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.

Subsequent Event

Subsequent Event	3 Months Ended
	Mar. 29, 2020
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event Prior to May 4, 2020, Pfizer’s Series A convertible perpetual preferred stock (the “Preferred Stock”) was held by an employee stock ownership plan trust (the “Trust”). On April 28, 2020, the independent fiduciary under the Trust directed the trustee and custodian of the Trust to convert all of the shares of the Preferred Stock held in the Trust to shares of Pfizer common stock, in accordance with the certificate of designations for the Preferred Stock. All outstanding shares of Preferred Stock were converted into shares of Pfizer common stock on May 4, 2020. The Trust received an aggregate of 1,070,369 shares of Pfizer common stock upon conversion, with zero shares of Preferred Stock remaining outstanding as a result of the conversion.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 29, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes in this Quarterly Report on Form 10-Q. We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three months ended February 23, 2020 and February 24, 2019 . The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three months ended March 29, 2020 and March 31, 2019 . Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year. We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2019 Financial Report. At the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new global structure consisting of three business segments––Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and through July 31, 2019 , Consumer Healthcare. Biopharma and Upjohn are the only reportable segments. For additional information, see Note 13 . Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan). As a result, revenues and expenses associated with Meridian and Mylan-Japan are reported in our Upjohn business beginning in the first quarter of 2020. In 2019, revenues and expenses from Meridian and Mylan-Japan were recorded in our Biopharma business. We performed certain reclassifications between the Biopharma and Upjohn segments to conform 2019 segment revenues and expenses associated with Meridian and Mylan-Japan to the current presentation. There was no impact to our consolidated financial statements. For additional information, see Note 13. As described in Notes to Consolidated Financial Statements— Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation in our 2019 Financial Report, recent acquisitions and the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture have impacted our results of operations. For additional information on the GSK Consumer Healthcare joint venture, see Note 2. Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.
Adoption of New Accounting Standards	Adoption of New Accounting Standards in 2020 On January 1, 2020 , we adopted four new accounting standards. Credit Losses on Financial Instruments ––We adopted a new accounting standard for credit losses on financial instruments, which replaces the probable initial recognition threshold for incurred loss estimates under prior guidance with a methodology that reflects expected credit loss estimates. The standard generally impacts financial assets that have a contractual right to receive cash and are not accounted for at fair value through net income, such as accounts receivable and held-to-maturity debt securities. The new guidance requires us to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for certain financial instruments, using information such as historical experience, current economic conditions and information, and the use of reasonable and supportable forecasted information. The standard also amends existing impairment guidance for available-for-sale debt securities to incorporate a credit loss allowance and allows for reversals of credit impairments in the event the issuer’s credit improves. We adopted the new accounting standard utilizing the modified retrospective method and, therefore, no adjustments were made to amounts in our prior period financial statements. The cumulative effect of adopting the standard as an adjustment to the opening balance of Retained earnings was not material. The impact of adoption did not have a material impact on our condensed consolidated statement of income or condensed consolidated statement of cash flows for the three months ended March 29, 2020 , nor on our condensed consolidated balance sheet as of March 29, 2020 . For additional information, see Note 1C . Goodwill Impairment Testing ––We prospectively adopted the new standard, which eliminates the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. Under the new guidance, the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, and recognizing an impairment charge for the amount by which the carrying amount of the reporting unit exceeds its fair value. There was no impact to our condensed consolidated financial statements from the adoption of this new standard. Implementation Costs in a Cloud Computing Arrangement ––We prospectively adopted the new standard related to customers’ accounting for implementation costs incurred in a cloud computing arrangement that is considered a service contract. The new guidance aligns the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The adoption of this guidance did not have a material impact on our condensed consolidated financial statements. Collaboration Agreements ––We prospectively adopted the new standard, which provides new guidance clarifying the interaction between the accounting for collaborative arrangements and revenue from contracts with customers. There was no impact to our condensed consolidated financial statements from the adoption of this new standard. On January 1, 2019, we adopted four new accounting standards. For additional information, see Notes to Consolidated Financial Statements–– Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2019 included in our 2019 Financial Report. C. Revenues and Trade Accounts Receivable Deductions from Revenues–– Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled $5.6 billion as of March 29, 2020 and $5.7 billion as of December 31, 2019 . The following table provides information about the balance sheet classification of these accruals: (MILLIONS OF DOLLARS) March 29, December 31, 2019 Reserve against Trade accounts receivable, less allowance for doubtful accounts $ 1,107 $ 1,257 Other current liabilities : Accrued rebates 3,408 3,285 Other accruals 553 581 Other noncurrent liabilities 577 565 Total accrued rebates and other accruals $ 5,645 $ 5,689 Trade Accounts Receivable–– Trade accounts receivable are stated at their net realizable value. The allowance for credit losses against gross trade accounts receivable reflects the best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables. In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted. During the first quarter of 2020 , additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements.

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 29, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Balance Sheet Classification of Accruals	The following table provides information about the balance sheet classification of these accruals: (MILLIONS OF DOLLARS) March 29, December 31, 2019 Reserve against Trade accounts receivable, less allowance for doubtful accounts $ 1,107 $ 1,257 Other current liabilities : Accrued rebates 3,408 3,285 Other accruals 553 581 Other noncurrent liabilities 577 565 Total accrued rebates and other accruals $ 5,645 $ 5,689

Acquisition and Equity-Method_2

Acquisition and Equity-Method Investment (Tables)	3 Months Ended
	Mar. 29, 2020
Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]
Equity Method Investment	Summarized financial information for our equity method investee, GSK Consumer Healthcare, as of and for the three months ending December 31, 2019, the most recent period available, is as follows: (MILLIONS OF DOLLARS) December 31, Current assets $ 7,537 Noncurrent assets 39,509 Total assets $ 47,046 Current liabilities $ 5,576 Noncurrent liabilities 5,321 Total liabilities $ 10,898 Equity attributable to shareholders $ 36,029 Equity attributable to noncontrolling interests 120 Total net equity $ 36,149 (MILLIONS OF DOLLARS) Three Months Ended December 31, 2019 Net sales $ 3,188 Cost of sales (1,811 ) Gross profit $ 1,377 Income from continuing operations 46 Net income 46 Income attributable to shareholders 37

Restructuring Charges and Oth_2

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)	3 Months Ended
	Mar. 29, 2020
Restructuring and Related Activities [Abstract]
Schedule of Components of Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives: Three Months Ended (MILLIONS OF DOLLARS) March 29, March 31, Restructuring charges/(credits): Employee terminations $ 25 $ (2 ) Asset impairments 31 9 Exit costs — 3 Restructuring charges (a) 56 10 Transaction costs (b) 3 — Integration costs and other (c) 10 36 Restructuring charges and certain acquisition-related costs 69 46 Net periodic benefit costs recorded in Other (income)/deductions––net 24 6 Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income as follows (d) : Cost of sales 5 9 Selling, informational and administrative expenses — 1 Research and development expenses (5 ) 3 Total additional depreciation––asset restructuring — 13 Implementation costs recorded in our condensed consolidated statements of income as follows (e) : Cost of sales 10 13 Selling, informational and administrative expenses 15 9 Research and development expenses — 4 Total implementation costs 24 26 Total costs associated with acquisitions and cost-reduction/productivity initiatives $ 117 $ 92 (a) In the first quarter of 2020 , restructuring charges mainly represent asset write-downs and employee termination costs associated with cost reduction initiatives. In the first quarter of 2019 , restructuring charges were primarily associated with cost reduction initiatives and mainly represent asset write-downs, partially offset by the reversal of previously recorded accruals for employee termination costs and asset impairments related to our acquisition of Hospira. The restructuring activities for the first quarter of 2020 are associated with the following: • Biopharma ( $2 million charge); Upjohn ( $13 million charge); and Other ( $41 million charge). The restructuring activities for the first quarter of 2019 are associated with the following: • Biopharma ( $13 million charge); Upjohn ( $13 million credit); and Other ( $10 million charge). (b) Transaction costs represent external costs for banking, legal, accounting and other similar services. In the first quarter of 2020, transaction costs relate to our acquisition of Array. (c) Integration costs and other represent external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the first quarter of 2020 , integration costs and other were mostly related to our acquisition of Array. In the first quarter of 2019 , integration costs and other were primarily related to our acquisition of Hospira. (d) Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions. (e) Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
Schedule of Components of and Changes in Restructuring Accruals	The following table provides the components of and changes in our restructuring accruals: (MILLIONS OF DOLLARS) Employee Termination Costs Asset Impairment Charges Exit Costs Accrual Balance, December 31, 2019 (a) $ 887 $ — $ 46 $ 933 Provision 25 31 — 56 Utilization and other (b) (243 ) (31 ) (1 ) (275 ) Balance, March 29, 2020 (c) $ 669 $ — $ 45 $ 714 (a) Included in Other current liabilities ( $714 million ) and Other noncurrent liabilities ( $219 million ). (b) Includes adjustments for foreign currency translation. (c) Included in Other current liabilities ( $532 million ) and Other noncurrent liabilities ( $182 million ).

Other (Income)_Deductions - N_2

Other (Income)/Deductions - Net (Tables)	3 Months Ended
	Mar. 29, 2020
Other Income and Expenses [Abstract]
Schedule of Other (Income)/Deductions - Net	The following table provides components of Other (income)/deductions––net : Three Months Ended (MILLIONS OF DOLLARS) March 29, March 31, Interest income (a) $ (34 ) $ (66 ) Interest expense (a) 390 361 Net interest expense 356 295 Royalty-related income (119 ) (89 ) Net (gains)/losses on asset disposals 1 (1 ) Net (gains)/losses recognized during the period on equity securities (b) 255 (111 ) Income from collaborations, out-licensing arrangements and sales of compound/product rights (c) (115 ) (82 ) Net periodic benefit credits other than service costs (d) (67 ) (40 ) Certain legal matters, net 10 4 Certain asset impairments (e) — 150 Business and legal entity alignment costs (f) — 119 Net losses on early retirement of debt — 138 GSK Consumer Healthcare JV equity method (income)/loss (g) 33 — Other, net (h) (132 ) (291 ) Other (income)/deductions––net $ 221 $ 92 (a) Interest income decreased in the first quarter of 2020 , primarily driven by a lower investment balance and lower short-term interest rates. Interest expense increased in the first quarter of 2020 , mainly as a result of an increased commercial paper balance due to the acquisition of Array. (b) The losses in the first quarter of 2020 , include, among other things, unrealized losses of $134 million related to our investment in Allogene. The gains in the first quarter of 2019 included, among other things, unrealized gains of $43 million related to our investment in Allogene. For additional information on investments, see Note 7B . (c) Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In the first quarter of 2020 , mainly includes, among other things, an upfront payment to us of $75 million from our sale of our CK1 assets to Biogen, Inc. In the first quarter of 2019 , primarily included $60 million in milestone income from Mylan Pharmaceuticals Inc. related to the FDA’s approval and launch of Wixela Inhub ® , a generic of Advair Diskus ® . (d) For additional information, see Note 10 . (e) In the first quarter of 2019 , primarily included intangible asset impairment charges of $130 million composed of: (i) $90 million related to WRDM IPR&D, for a pre-clinical stage asset from our acquisition of Bamboo for gene therapies for the potential treatment of patients with certain rare diseases, which was the result of a determination to not use certain Bamboo IPR&D acquired in future rare disease development and (ii) $40 million related to a Biopharma developed technology right, acquired in connection with our acquisition of King, for government defense products and reflects, among other things, updated commercial forecasts including manufacturing cost assumptions. In addition, the first quarter of 2019 included other asset impairments of $20 million . (f) In the first quarter of 2019, represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services. (g) See Note 2B for additional information. (h) The first quarter of 2020 includes, among other things, dividend income of $77 million from our investment in ViiV. The first quarter of 2019 included, among other things, credits of $72 million , reflecting the change in the fair value of contingent consideration, and dividend income of $64 million from our investment in ViiV.

Tax Matters (Tables)

Tax Matters (Tables)	3 Months Ended
	Mar. 29, 2020
Income Tax Disclosure [Abstract]
Schedule of Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)	The following table provides the components of Tax provision/(benefit) on other comprehensive income/(loss) : Three Months Ended (MILLIONS OF DOLLARS) March 29, March 31, Foreign currency translation adjustments, net (a) $ (252 ) $ 27 Unrealized holding gains/(losses) on derivative financial instruments, net (133 ) 59 Reclassification adjustments for (gains)/losses included in net income 15 (55 ) (118 ) 4 Unrealized holding gains/(losses) on available-for-sale securities, net (6 ) 5 Reclassification adjustments for losses included in net income 2 1 (5 ) 7 Benefit plans: actuarial losses, net (21 ) — Reclassification adjustments related to amortization 15 3 Reclassification adjustments related to settlements, net 9 — Other 4 (5 ) 8 (2 ) Reclassification adjustments related to amortization of prior service costs and other, net (11 ) (11 ) Other — — (11 ) (11 ) Tax provision/(benefit) on other comprehensive income/(loss) $ (377 ) $ 25 (a) Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)	3 Months Ended
	Mar. 29, 2020
Equity [Abstract]
Schedule of Changes in Accumulated Other Comprehensive Loss, Net of Tax	The following table provides the changes, net of tax, in Accumulated other comprehensive loss : Net Unrealized Gains/(Losses) Benefit Plans (MILLIONS OF DOLLARS) Foreign Currency Translation Adjustments Derivative Financial Instruments Available-For-Sale Securities Actuarial Gains/(Losses) Prior Service (Costs)/Credits and Other Accumulated Other Comprehensive Income/(Loss) Balance, December 31, 2019 $ (5,952 ) $ 20 $ (35 ) $ (6,257 ) $ 584 $ (11,640 ) Other comprehensive income/(loss) (a) (1,020 ) (364 ) (32 ) (39 ) (35 ) (1,490 ) Balance, March 29, 2020 $ (6,973 ) $ (344 ) $ (67 ) $ (6,296 ) $ 549 $ (13,131 ) (a) Includes after-tax losses of approximately $1.2 billion related to foreign currency translation adjustments attributable to our equity method investment in GSK Consumer Healthcare (see Note 2B ), partially offset by the results of our net investment hedging program.

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended
	Mar. 29, 2020
Financial Instruments [Abstract]
Schedule of Financial Assets and Liabilities Measured At Fair Value On a Recurring Basis	The following table presents the financial assets and liabilities measured at fair value using a market approach on a recurring basis by balance sheet categories and fair value hierarchy level as defined in Notes to Consolidated Financial Statements–– Note 1E. Basis of Presentation and Significant Accounting Policies: Fair Value in our 2019 Financial Report: March 29, 2020 December 31, 2019 (MILLIONS OF DOLLARS) Total Level 1 Level 2 Total Level 1 Level 2 Financial assets measured at fair value on a recurring basis: Short-term investments Classified as equity securities with readily determinable fair values: Money market funds $ 4,190 $ — $ 4,190 $ 705 $ — $ 705 Classified as available-for-sale debt securities: Government and agency—non-U.S. 1,989 — 1,989 4,863 — 4,863 Government and agency—U.S. 16 — 16 811 — 811 Corporate and other 806 — 806 1,013 — 1,013 2,812 — 2,812 6,687 — 6,687 Total short-term investments 7,002 — 7,002 7,392 — 7,392 Other current assets Derivative assets: Interest rate contracts 15 — 15 53 — 53 Foreign exchange contracts 688 — 688 413 — 413 Total other current assets 702 — 702 465 — 465 Long-term investments Classified as equity securities with readily determinable fair values (a) 1,603 1,581 22 1,902 1,863 39 Classified as available-for-sale debt securities: Government and agency—U.S. 285 — 285 303 — 303 Corporate and other 11 — 11 11 — 11 296 — 296 315 — 315 Total long-term investments 1,899 1,581 318 2,216 1,863 354 Other noncurrent assets Derivative assets: Interest rate contracts 134 — 134 266 — 266 Foreign exchange contracts 356 — 356 261 — 261 Total derivative assets 490 — 490 526 — 526 Insurance contracts (b) 530 — 530 575 — 575 Total other noncurrent assets 1,020 — 1,020 1,102 — 1,102 Total assets $ 10,623 $ 1,581 $ 9,042 $ 11,176 $ 1,863 $ 9,313 Financial liabilities measured at fair value on a recurring basis: Other current liabilities Derivative liabilities: Foreign exchange contracts $ 109 $ — $ 109 $ 114 $ — $ 114 Total other current liabilities 109 — 109 114 — 114 Other noncurrent liabilities Derivative liabilities: Foreign exchange contracts 1,139 — 1,139 604 — 604 Total other noncurrent liabilities 1,139 — 1,139 604 — 604 Total liabilities $ 1,248 $ — $ 1,248 $ 718 $ — $ 718 (a) As of March 29, 2020 , long-term equity securities of $155 million and as of December 31, 2019 , long-term equity securities of $176 million were held in restricted trusts for benefits attributable to various U.S. non-qualified employee benefit plans. (b) Other noncurrent assets include life insurance policies held in restricted trusts attributable to the funding of various U.S. non-qualified employee benefit plans. The underlying invested assets in these insurance contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions –– net in the consolidated statements of income (see Note 4 ).
Schedule of Financial Liabilities Not Measured At Fair Value On a Recurring Basis	The following table presents the financial liabilities not measured at fair value on a recurring basis, including the carrying values and estimated fair values using a market approach: March 29, 2020 December 31, 2019 Carrying Value Estimated Fair Value Carrying Value Estimated Fair Value (MILLIONS OF DOLLARS) Total Level 2 Total Level 2 Financial Liabilities Long-term debt, excluding the current portion $ 36,281 $ 40,062 $ 40,062 $ 35,955 $ 40,842 $ 40,842
Investments by Classification Type	The following table represents our investments by classification type: (MILLIONS OF DOLLARS) March 29, December 31, Short-term investments Equity securities with readily determinable fair values (a) $ 4,190 $ 705 Available-for-sale debt securities 2,812 6,687 Held-to-maturity debt securities 1,198 1,133 Total Short-term investments $ 8,199 $ 8,525 Long-term investments Equity securities with readily determinable fair values $ 1,603 $ 1,902 Available-for-sale debt securities 296 315 Held-to-maturity debt securities 40 42 Private equity securities at cost 757 756 Total Long-term investments $ 2,696 $ 3,014 Equity-method investments 15,524 17,133 Total long-term investments and equity-method investments $ 18,220 $ 20,147 Held-to-maturity cash equivalents $ 401 $ 163 (a) As of March 29, 2020 and December 31, 2019 , equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt.
Schedule of Held-to-maturity Securities	At March 29, 2020, our investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt securities at March 29, 2020 and December 31, 2019 is as follows, including, as of March 29, 2020, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities: March 29, 2020 December 31, 2019 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS OF DOLLARS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 Over 5 Total Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency –– non-U.S. $ 2,056 $ — $ (67 ) $ 1,989 $ 1,989 $ — $ — $ 1,989 $ 4,895 $ 6 $ (38 ) $ 4,863 Government and agency––U.S. 305 — (4 ) 302 16 285 — 302 1,120 — (6 ) 1,114 Corporate and other (a) 823 — (6 ) 817 807 11 — 817 1,027 — (2 ) 1,025 Held-to-maturity debt securities Time deposits and other 624 — — 624 589 8 28 624 535 — — 535 Government and agency –– non-U.S. 1,014 — — 1,014 1,010 — 4 1,014 803 — — 803 Total debt securities $ 4,823 $ 1 $ (77 ) $ 4,746 $ 4,410 $ 304 $ 32 $ 4,746 $ 8,380 $ 6 $ (47 ) $ 8,340 (a) Primarily issued by a diverse group of corporations.
Schedule of Available-for-sale Securities	At March 29, 2020, our investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt securities at March 29, 2020 and December 31, 2019 is as follows, including, as of March 29, 2020, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities: March 29, 2020 December 31, 2019 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS OF DOLLARS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 Over 5 Total Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency –– non-U.S. $ 2,056 $ — $ (67 ) $ 1,989 $ 1,989 $ — $ — $ 1,989 $ 4,895 $ 6 $ (38 ) $ 4,863 Government and agency––U.S. 305 — (4 ) 302 16 285 — 302 1,120 — (6 ) 1,114 Corporate and other (a) 823 — (6 ) 817 807 11 — 817 1,027 — (2 ) 1,025 Held-to-maturity debt securities Time deposits and other 624 — — 624 589 8 28 624 535 — — 535 Government and agency –– non-U.S. 1,014 — — 1,014 1,010 — 4 1,014 803 — — 803 Total debt securities $ 4,823 $ 1 $ (77 ) $ 4,746 $ 4,410 $ 304 $ 32 $ 4,746 $ 8,380 $ 6 $ (47 ) $ 8,340 (a) Primarily issued by a diverse group of corporations.
Contractual Maturities of Available-for-sale and Held-to-maturity Debt Securities	At March 29, 2020, our investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt securities at March 29, 2020 and December 31, 2019 is as follows, including, as of March 29, 2020, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities: March 29, 2020 December 31, 2019 Gross Unrealized Maturities (in Years) Gross Unrealized (MILLIONS OF DOLLARS) Amortized Cost Gains Losses Fair Value Within 1 Over 1 Over 5 Total Amortized Cost Gains Losses Fair Value Available-for-sale debt securities Government and agency –– non-U.S. $ 2,056 $ — $ (67 ) $ 1,989 $ 1,989 $ — $ — $ 1,989 $ 4,895 $ 6 $ (38 ) $ 4,863 Government and agency––U.S. 305 — (4 ) 302 16 285 — 302 1,120 — (6 ) 1,114 Corporate and other (a) 823 — (6 ) 817 807 11 — 817 1,027 — (2 ) 1,025 Held-to-maturity debt securities Time deposits and other 624 — — 624 589 8 28 624 535 — — 535 Government and agency –– non-U.S. 1,014 — — 1,014 1,010 — 4 1,014 803 — — 803 Total debt securities $ 4,823 $ 1 $ (77 ) $ 4,746 $ 4,410 $ 304 $ 32 $ 4,746 $ 8,380 $ 6 $ (47 ) $ 8,340 (a) Primarily issued by a diverse group of corporations.
Schedule of Gains and Losses on Investment Securities	The following table presents the net unrealized (gains) and losses for the period that relate to equity securities, excluding equity method investments, still held at the reporting date, calculated as follows: Three Months Ended (MILLIONS OF DOLLARS) March 29, March 31, Net (gains)/losses recognized during the period on equity securities (a ) $ 255 $ (111 ) Less: Net gains recognized during the period on equity securities sold during the period (19 ) (5 ) Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date (b) $ 274 $ (106 ) (a) The net gains on investments in equity securities are reported in Other (income)/deductions –– net. For additional information, see Note 4 . (b) Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of $58 million and upward adjustments of $60 million . Impairments, downward and upward adjustments were not significant in the first quarter of 2020 and 2019 .
Schedule of Short-term Borrowings	Short-term borrowings include: (MILLIONS OF DOLLARS) March 29, December 31, Commercial paper $ 14,908 $ 13,915 Current portion of long-term debt, principal amount 334 1,458 Other short-term borrowings, principal amount (a) 800 860 Total short-term borrowings, principal amount 16,042 16,233 Net fair value adjustments related to hedging and purchase accounting 3 5 Net unamortized discounts, premiums and debt issuance costs (38 ) (43 ) Total Short-term borrowings, including current portion of long-term debt , carried at historical proceeds, as adjusted $ 16,007 $ 16,195 (a) Other short-term borrowings primarily include cash collateral. For additional information, see Note 7E
Schedule of Principal Amounts of Senior Unsecured Long-Term Debt and Adjustments	The following table provides the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt: (MILLIONS OF DOLLARS) March 29, December 31, Total long-term debt, principal amount $ 34,778 $ 34,820 Net fair value adjustments related to hedging and purchase accounting 1,671 1,305 Net unamortized discounts, premiums and debt issuance costs (173 ) (176 ) Other long-term debt 5 5 Total long-term debt, carried at historical proceeds, as adjusted $ 36,281 $ 35,955 Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above) $ 337 $ 1,462 In the first quarter of 2020, we issued the following senior unsecured notes: (MILLIONS OF DOLLARS) Principal Interest Rate Maturity Date As of March 29, 2020 2.625% notes (a) April 1, 2030 $ 1,250 Total long-term debt issued in the first quarter of 2020 (b) $ 1,250 (a) Fixed rate notes may be redeemed by us at any time, in whole, or in part, at a redemption price plus accrued and unpaid interest. (b) The effective interest rate for the notes at issuance was 2.67% .
Schedule of Derivative Instruments	The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments: (MILLIONS OF DOLLARS) March 29, 2020 December 31, 2019 Fair Value Fair Value Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments: Foreign exchange contracts (a) $ 23,877 $ 955 $ 1,150 $ 25,193 $ 591 $ 662 Interest rate contracts 1,995 148 — 6,645 318 — 1,103 1,150 909 662 Derivatives not designated as hedging instruments: Foreign exchange contracts $ 13,402 89 97 $ 19,623 82 55 Total $ 1,192 $ 1,248 $ 992 $ 718 (a) The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $5.3 billion as of March 29, 2020 and $5.9 billion as of December 31, 2019.
Schedule of Derivative Assets	The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments: (MILLIONS OF DOLLARS) March 29, 2020 December 31, 2019 Fair Value Fair Value Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments: Foreign exchange contracts (a) $ 23,877 $ 955 $ 1,150 $ 25,193 $ 591 $ 662 Interest rate contracts 1,995 148 — 6,645 318 — 1,103 1,150 909 662 Derivatives not designated as hedging instruments: Foreign exchange contracts $ 13,402 89 97 $ 19,623 82 55 Total $ 1,192 $ 1,248 $ 992 $ 718 (a) The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $5.3 billion as of March 29, 2020 and $5.9 billion as of December 31, 2019.
Schedule of Derivative Liabilities	The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments: (MILLIONS OF DOLLARS) March 29, 2020 December 31, 2019 Fair Value Fair Value Notional Asset Liability Notional Asset Liability Derivatives designated as hedging instruments: Foreign exchange contracts (a) $ 23,877 $ 955 $ 1,150 $ 25,193 $ 591 $ 662 Interest rate contracts 1,995 148 — 6,645 318 — 1,103 1,150 909 662 Derivatives not designated as hedging instruments: Foreign exchange contracts $ 13,402 89 97 $ 19,623 82 55 Total $ 1,192 $ 1,248 $ 992 $ 718 (a) The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $5.3 billion as of March 29, 2020 and $5.9 billion as of December 31, 2019.
Information about Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk	The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk: Amount of (a) Amount of Gains/(Losses) (a) , (b) Amount of Gains/(Losses) (a), (b) (MILLIONS OF DOLLARS) March 29, March 31, March 29, March 31, March 29, March 31, Three Months Ended Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign exchange contracts (c) $ — $ — $ (529 ) $ 210 $ (46 ) $ 209 Amount excluded from effectiveness testing recognized in earnings based on an amortization approach (d) — — 29 56 27 54 Derivative Financial Instruments in Fair Value Hedge Relationships: Interest rate contracts 386 329 — — — — Hedged item (386 ) (329 ) — — — — Foreign exchange contracts — — — — — — Hedged item — — — — — — Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign exchange contracts — — 384 23 — — The portion on foreign exchange contracts excluded from the assessment of hedge effectiveness (d) — — 147 41 41 24 Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency short-term borrowings (e) — — 8 35 — — Foreign currency long-term debt (e) — — 45 38 — — Derivative Financial Instruments Not Designated as Hedges: Foreign exchange contracts (59 ) (120 ) — — — — All other net (d) — — (1 ) 1 — — $ (59 ) $ (120 ) $ 83 $ 404 $ 23 $ 286 (a) OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of income . COS = Cost of Sales, included in Cost of sales in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income . (b) For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in Other comprehensive income/(loss)––Unrealized holding gains/(losses) on derivative financial instruments, net . For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the gains and losses are included in Other comprehensive income/(loss)––Foreign currency translation adjustments, net. (c) The amounts reclassified from OCI into COS were a net gain of $70 million in the first quarter of 2020 and a net gain of $44 million in the first quarter of 2019. The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $220 million within the next 12 months into Cost of sales. The maximum length of time over which we are hedging future foreign exchange cash flow relates to our $1.8 billion U.K. pound debt maturing in 2043. (d) The amounts reclassified from OCI were reclassified into OID. (e) Long-term debt includes foreign currency long-term borrowings with carrying values of $1.9 billion as of March 29, 2020 , which are used as hedging instruments in net investment hedges.
Schedule of Total Amount of Each Income and Expense Line in which Results of Fair Value Hedges are Recorded	The following table provides the amounts recorded in our condensed consolidated balance sheet related to cumulative basis adjustments for fair value hedges: March 29, 2020 December 31, 2019 Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount (MILLIONS OF DOLLARS) Carrying Amount of Hedged Assets/Liabilities (a) Active Hedging Relationships Discontinued Hedging Relationships Carrying Amount of Hedged Assets/Liabilities (a) Active Hedging Relationships Discontinued Hedging Relationships Long-term investments $ 45 $ — $ — $ 45 $ — $ — Long-term debt 2,027 134 1,196 7,092 266 690 (a) Carrying amounts exclude the cumulative amount of fair value hedging adjustments.

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 29, 2020
Inventory Disclosure [Abstract]
Schedule of Components of Inventories, Current	The following table provides the components of Inventories : (MILLIONS OF DOLLARS) March 29, December 31, Finished goods $ 2,703 $ 2,750 Work-in-process 4,962 4,743 Raw materials and supplies 757 790 Inventories (a) $ 8,423 $ 8,283 Noncurrent inventories not included above (b) $ 720 $ 714 (a) The change from December 31, 2019 reflects increases for certain products, including inventory build for new product launches, market demand and network strategy, partially offset by a decrease due to foreign exchange. (b) Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.
Schedule of Components of Inventories, Noncurrent	The following table provides the components of Inventories : (MILLIONS OF DOLLARS) March 29, December 31, Finished goods $ 2,703 $ 2,750 Work-in-process 4,962 4,743 Raw materials and supplies 757 790 Inventories (a) $ 8,423 $ 8,283 Noncurrent inventories not included above (b) $ 720 $ 714 (a) The change from December 31, 2019 reflects increases for certain products, including inventory build for new product launches, market demand and network strategy, partially offset by a decrease due to foreign exchange. (b) Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.

Identifiable Intangible Asset_2

Identifiable Intangible Assets and Goodwill (Tables)	3 Months Ended
	Mar. 29, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	The following table provides the components of Identifiable intangible assets : March 29, 2020 December 31, 2019 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights $ 88,519 $ (63,783 ) $ 24,736 $ 88,730 $ (63,106 ) $ 25,625 Brands 922 (749 ) 173 922 (741 ) 181 Licensing agreements and other 1,779 (1,206 ) 574 1,772 (1,191 ) 582 91,221 (65,738 ) 25,482 91,425 (65,037 ) 26,387 Indefinite-lived intangible assets Brands 1,991 1,991 1,991 1,991 IPR&D (a) 5,918 5,918 5,919 5,919 Licensing agreements and other 1,073 1,073 1,073 1,073 8,982 8,982 8,983 8,983 Identifiable intangible assets (a) $ 100,203 $ (65,738 ) $ 34,464 $ 100,408 $ (65,037 ) $ 35,370 (a) The decrease in I dentifiable intangible assets, less accumulated amortization , is primarily due to amortization.
Schedule of Indefinite Lived Intangible Assets	The following table provides the components of Identifiable intangible assets : March 29, 2020 December 31, 2019 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights $ 88,519 $ (63,783 ) $ 24,736 $ 88,730 $ (63,106 ) $ 25,625 Brands 922 (749 ) 173 922 (741 ) 181 Licensing agreements and other 1,779 (1,206 ) 574 1,772 (1,191 ) 582 91,221 (65,738 ) 25,482 91,425 (65,037 ) 26,387 Indefinite-lived intangible assets Brands 1,991 1,991 1,991 1,991 IPR&D (a) 5,918 5,918 5,919 5,919 Licensing agreements and other 1,073 1,073 1,073 1,073 8,982 8,982 8,983 8,983 Identifiable intangible assets (a) $ 100,203 $ (65,738 ) $ 34,464 $ 100,408 $ (65,037 ) $ 35,370 (a) The decrease in I dentifiable intangible assets, less accumulated amortization , is primarily due to amortization.
Identifiable Intangible Assets as a Percentage of Total Identifiable Intangible Assets Less Accumulated Amortization, By Segment	Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization: March 29, 2020 Biopharma Upjohn WRDM Developed technology rights 99 % 1 % — Brands, finite-lived 100 % — — Brands, indefinite-lived 42 % 58 % — IPR&D 95 % — 5 % Licensing agreements and other, finite-lived 97 % 1 % 1 % Licensing agreements and other, indefinite-lived 100 % — —
Schedule of Goodwill	The following table provides the components of and changes in the carrying amount of Goodwill : (MILLIONS OF DOLLARS) Biopharma Upjohn Total Balance, December 31, 2019 $ 48,202 $ 10,451 $ 58,653 Other (a) (122 ) (30 ) (151 ) Balance, March 29, 2020 $ 48,081 $ 10,421 $ 58,502 (a) Represents the impact of foreign exchange.

Pension and Postretirement Be_2

Pension and Postretirement Benefit Plans (Tables)	3 Months Ended
	Mar. 29, 2020
Retirement Benefits [Abstract]
Schedule of Net Periodic Benefit Costs	The following table provides the components of net periodic benefit cost/(credit): Three Months Ended Pension Plans U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans (MILLIONS OF DOLLARS) March 29, March 31, March 29, March 31, March 29, March 31, March 29, March 31, Service cost $ — $ — $ — $ — $ 36 $ 32 $ 10 $ 9 Interest cost 131 157 10 12 42 54 13 19 Expected return on plan assets (252 ) (223 ) — — (78 ) (80 ) (9 ) (8 ) Amortization of: Actuarial losses 32 37 4 2 31 20 — 1 Prior service credits (1 ) (1 ) — — (1 ) (1 ) (43 ) (45 ) Settlements 14 1 38 — 1 — — — Special termination benefits — — 1 6 — — — — $ (76 ) $ (28 ) $ 52 $ 20 $ 32 $ 25 $ (30 ) $ (23 ) The following table provides the amounts we contributed, and the amounts we expect to contribute during 2020, to our pension and postretirement plans from our general assets for the periods indicated: Pension Plans (MILLIONS OF DOLLARS) U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans Contributions from our general assets for the three months ended March 29, 2020 $ 3 $ 132 $ 46 $ 45 Expected contributions from our general assets during 2020 (a) 1,276 228 186 155
Schedule of Employer Contributions to Pension and Postretirement Plans	The following table provides the amounts we contributed, and the amounts we expect to contribute during 2020, to our pension and postretirement plans from our general assets for the periods indicated: Pension Plans (MILLIONS OF DOLLARS) U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans Contributions from our general assets for the three months ended March 29, 2020 $ 3 $ 132 $ 46 $ 45 Expected contributions from our general assets during 2020 (a) 1,276 228 186 155 (a) Contributions expected to be made for 2020 are inclusive of amounts contributed during the three months ended March 29, 2020 . The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments. For the U.S. qualified plans, we plan to make a $1.25 billion voluntary contribution in the second half of 2020.

Earnings Per Common Share Att_2

Earnings Per Common Share Attributable to Common Shareholders (Tables)	3 Months Ended
	Mar. 29, 2020
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Earning Per Share	The following table provides the detailed calculation of EPS : Three Months Ended (IN MILLIONS) March 29, March 31, EPS Numerator––Basic Income from continuing operations $ 3,410 $ 3,889 Less: Net income attributable to noncontrolling interests 9 6 Income from continuing operations attributable to Pfizer Inc. 3,401 3,884 Less: Preferred stock dividends––net of tax — — Income from continuing operations attributable to Pfizer Inc. common shareholders 3,401 3,883 Discontinued operations––net of tax — — Net income attributable to Pfizer Inc. common shareholders $ 3,401 $ 3,883 EPS Numerator––Diluted Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions $ 3,401 $ 3,884 Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions — — Net income attributable to Pfizer Inc. common shareholders and assumed conversions $ 3,401 $ 3,884 EPS Denominator Weighted-average number of common shares outstanding––Basic 5,545 5,635 Common-share equivalents: stock options, stock issuable under employee compensation plans and convertible preferred stock 68 115 Weighted-average number of common shares outstanding––Diluted 5,613 5,750 Anti-dilutive common stock equivalents (a) 3 2 (a) These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Segment, Geographic and Other_2

Segment, Geographic and Other Revenue Information (Tables)	3 Months Ended
	Mar. 29, 2020
Segment Reporting [Abstract]
Reconciliation of Revenue from Segments to Consolidated	The following table provides selected income statement information by reportable segment: Three Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) March 29, March 31, March 29, March 31, Reportable Segments: Biopharma $ 10,007 $ 9,045 $ 6,729 $ 5,883 Upjohn 2,022 3,214 1,191 2,279 Total reportable segments 12,028 12,259 7,920 8,162 Other business activities — 858 (1,489 ) (1,113 ) Reconciling Items: Corporate and other unallocated — — (1,110 ) (1,278 ) Purchase accounting adjustments — — (812 ) (1,038 ) Acquisition-related costs — — (13 ) (28 ) Certain significant items (b) — — (612 ) (382 ) $ 12,028 $ 13,118 $ 3,885 $ 4,323 (a) Income from continuing operations before provision for taxes on income . Biopharma’s earnings include d ividend income of $77 million in the first quarter of 2020 and $64 million in the first quarter of 2019 from our investment in ViiV. For additional information, see Note 4. (b) Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	The following table provides selected income statement information by reportable segment: Three Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) March 29, March 31, March 29, March 31, Reportable Segments: Biopharma $ 10,007 $ 9,045 $ 6,729 $ 5,883 Upjohn 2,022 3,214 1,191 2,279 Total reportable segments 12,028 12,259 7,920 8,162 Other business activities — 858 (1,489 ) (1,113 ) Reconciling Items: Corporate and other unallocated — — (1,110 ) (1,278 ) Purchase accounting adjustments — — (812 ) (1,038 ) Acquisition-related costs — — (13 ) (28 ) Certain significant items (b) — — (612 ) (382 ) $ 12,028 $ 13,118 $ 3,885 $ 4,323 (a) Income from continuing operations before provision for taxes on income . Biopharma’s earnings include d ividend income of $77 million in the first quarter of 2020 and $64 million in the first quarter of 2019 from our investment in ViiV. For additional information, see Note 4. (b) Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.
Schedule of Revenues by Geographic Region	The following table provides revenues by geographic area: Three Months Ended (MILLIONS OF DOLLARS) March 29, March 31, % Change United States $ 5,651 $ 6,175 (8 ) Developed Europe (a) 1,921 2,086 (8 ) Developed Rest of World (b) 1,456 1,535 (5 ) Emerging Markets (c) 3,001 3,322 (10 ) Revenues $ 12,028 $ 13,118 (8 ) (a) Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.5 billion in the first quarter of 2020 and $1.7 billion in the first quarter of 2019 . (b) Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand. (c) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.
Schedule of Significant Product Revenues	The following table provides detailed revenue information for several of our major products: (MILLIONS OF DOLLARS) Three Months Ended PRODUCT PRIMARY INDICATION OR CLASS March 29, March 31, TOTAL REVENUES $ 12,028 $ 13,118 PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA) $ 10,007 $ 9,045 Internal Medicine (a) $ 2,332 $ 2,137 Eliquis alliance revenues and direct sales Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism 1,300 1,011 Chantix/Champix An aid to smoking cessation treatment in adults 18 years of age or older 270 273 Premarin family Symptoms of menopause 152 168 BMP2 Development of bone and cartilage 69 67 Toviaz Overactive bladder 60 60 All other Internal Medicine Various 480 559 Oncology $ 2,435 $ 1,961 Ibrance Metastatic breast cancer 1,248 1,133 Xtandi alliance revenues Non-metastatic and metastatic castration-resistant prostate cancer and non-metastatic castration-sensitive prostate cancer 209 168 Sutent Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor 205 232 Inlyta Advanced RCC 169 73 Xalkori ALK-positive and ROS1-positive advanced NSCLC 149 123 Bosulif Philadelphia chromosome–positive chronic myelogenous leukemia 100 80 Retacrit (b) Anemia 89 31 Braftovi In combination with Mektovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation and, in combination with Erbitux ® (cetuximab), for the treatment of BRAF V600E -mutant metastatic colorectal cancer after prior therapy 37 — Mektovi In combination with Braftovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation 37 — All other Oncology Various 192 122 Hospital (a), (c) $ 2,012 $ 1,827 Sulperazon Bacterial infections 187 177 Zithromax Bacterial infections 138 104 Medrol Anti-inflammatory glucocorticoid 129 120 Vfend Fungal infections 74 85 Panzyga Primary humoral immunodeficiency 74 17 Zyvox Bacterial infections 70 64 Fragmin Treatment/prevention of venous thromboembolism 59 60 Pfizer CentreOne (d) Various 152 176 All other Anti-infectives Various 444 405 All other Hospital (c) Various 684 620 Vaccines $ 1,611 $ 1,612 Prevnar 13/Prevenar 13 Pneumococcal disease 1,450 1,486 Nimenrix Meningococcal disease 75 50 All other Vaccines Various 86 77 Inflammation & Immunology (I&I) $ 978 $ 1,037 Xeljanz RA, PsA, UC 451 423 Enbrel (Outside the U.S. and Canada) RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis 347 451 Inflectra/Remsima (b) Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis 158 138 All other I&I Various 22 25 Rare Disease $ 639 $ 470 Vyndaqel/Vyndamax ATTR-cardiomyopathy and polyneuropathy 231 41 BeneFIX Hemophilia B 121 125 Genotropin Replacement of human growth hormone 103 107 Refacto AF/Xyntha Hemophilia A 89 106 Somavert Acromegaly 64 59 All other Rare Disease Various 31 31 (MILLIONS OF DOLLARS) Three Months Ended PRODUCT PRIMARY INDICATION OR CLASS March 29, March 31, UPJOHN (a) $ 2,022 $ 3,214 Lipitor Reduction of LDL cholesterol 405 622 Lyrica Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury 357 1,186 Norvasc Hypertension 197 300 Celebrex Arthritis pain and inflammation, acute pain 156 174 Viagra Erectile dysfunction 127 145 Zoloft Depression and certain anxiety disorders 78 69 Effexor Depression and certain anxiety disorders 77 77 EpiPen (a) Epinephrine injection used in treatment of life-threatening allergic reactions 72 56 Xalatan/Xalacom Glaucoma and ocular hypertension 61 62 All other Upjohn Various 492 523 CONSUMER HEALTHCARE BUSINESS (e) $ — $ 858 Total Alliance revenues Various $ 1,382 $ 1,090 Total Biosimilars (b) Various $ 288 $ 179 Total Sterile Injectable Pharmaceuticals (f) $ 1,407 $ 1,237 (a) Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan). As a result, revenues associated with our Meridian subsidiary, except for product revenues for EpiPen sold in Canada, and Mylan-Japan, are reported in our Upjohn business beginning in the first quarter of 2020. We have reclassified revenues associated with our Meridian subsidiary and Mylan-Japan from the Hospital and Internal Medicine categories to the Upjohn business to conform 2019 product revenues to the current presentation. (b) Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit. (c) Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. Hospital also includes Pfizer CentreOne (d) . All other Hospital primarily includes revenues from legacy Sterile Injectables Pharmaceuticals (SIP) products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in “All other Anti-infectives”. (d) Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements. (e) On July 31, 2019 , Pfizer’s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK’s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see Note 2B . (f) Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.

Basis of Presentation and Sig_4

Basis of Presentation and Significant Accounting Policies (Details) $ in Millions	7 Months Ended
	Jul. 31, 2019Operating_Segment	Mar. 29, 2020USD ($)	Jan. 01, 2020Accounting_standard	Dec. 31, 2019USD ($)	Jan. 01, 2019Accounting_standard
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of business segments | Operating_Segment	3
Number of accounting standards adopted | Accounting_standard			4		4
Accrued rebates and other accruals | $		$ 5,645		$ 5,689

Basis of Presentation and Sig_5

Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details) - USD ($) $ in Millions	Mar. 29, 2020	Dec. 31, 2019
Schedule Of Accrued Liabilities [Line Items]
Accrued rebates and other accruals	$ 5,645	$ 5,689
Trade accounts receivable, less allowance for doubtful accounts [Member]
Schedule Of Accrued Liabilities [Line Items]
Accrued rebates and other accruals	1,107	1,257
Other current liabilities [Member]
Schedule Of Accrued Liabilities [Line Items]
Accrued rebates	3,408	3,285
Other accruals	553	581
Other noncurrent liabilities [Member]
Schedule Of Accrued Liabilities [Line Items]
Accrued rebates and other accruals	$ 577	$ 565

Acquisition and Equity-Method_3

Acquisition and Equity-Method Investment - Array BioPharma (Details) - Array [Member] $ / shares in Units, $ in Billions	Jul. 30, 2019USD ($)$ / shares
Business Acquisition [Line Items]
Business acquisition, per share in cash (in dollars per share) | $ / shares	$ 48
Payments for acquisition, cash portion	$ 11.2
Acquisition of business, net of cash acquired	$ 10.9

Acquisition and Equity-Method_4

Acquisition and Equity-Method Investment - Equity Method Investment Narrative (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 29, 2020	Sep. 29, 2019	Mar. 31, 2019	Dec. 31, 2019	Jul. 31, 2019
Schedule of Equity Method Investments [Line Items]
Gain on completion of Consumer Healthcare JV transaction	[1]	$ 6		$ 0
Equity-method investments	[2]	15,524			$ 17,133
GSK Consumer Healthcare [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage						32.00%
Gain on completion of Consumer Healthcare JV transaction			$ 8,100
Gain on completion of Consumer Healthcare JV transaction, after-tax			$ 5,400
Equity-method investments		15,400			17,000
Equity method investment earnings		$ 11
Fair value of equity method investment						$ 15,700
Underlying equity in net assets					11,000	11,200
Difference between carrying amount and underlying equity					$ 4,800	$ 4,500
Excess basis amortization period		17 years
GSK [Member] | GSK Consumer Healthcare [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage						68.00%
OID [Member] | GSK Consumer Healthcare [Member]
Schedule of Equity Method Investments [Line Items]
Excess basis amortization		$ 44
Consumer Healthcare [Member] | Held-for-sale [Member]
Schedule of Equity Method Investments [Line Items]
Pre-tax income attributable to disposal group				$ 281
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.

Acquisition and Equity-Method_5

Acquisition and Equity-Method Investment - Schedule of Equity-Method Investment (Details) - GSK Consumer Healthcare [Member] $ in Millions	3 Months Ended
	Dec. 31, 2019USD ($)
Schedule of Equity Method Investments [Line Items]
Current assets	$ 7,537
Noncurrent assets	39,509
Total assets	47,046
Current liabilities	5,576
Noncurrent liabilities	5,321
Total liabilities	10,898
Equity attributable to shareholders	36,029
Equity attributable to noncontrolling interests	120
Total net equity	36,149
Net sales	3,188
Cost of sales	(1,811)
Gross profit	1,377
Income from continuing operations	46
Net income	46
Income attributable to shareholders	$ 37

Restructuring Charges and Oth_3

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 29, 2020	Mar. 31, 2019	Mar. 29, 2020
Focused Company Plan [Member]
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost	$ 1,200		$ 1,200
Percentage of expected costs to be non-cash	10.00%
Restructuring costs incurred	$ 117		$ 160
2017-2019 Initiatives and Organizing for Growth [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred		$ 92

Restructuring Charges and Oth_4

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) - USD ($) $ in Millions		3 Months Ended
		Mar. 29, 2020	Mar. 31, 2019
Restructuring charges:
Employee terminations		$ 25	$ (2)
Asset impairments		31	9
Exit costs		0	3
Restructuring charges/(credits)	[1]	56	10
Transaction costs	[2]	3	0
Integration costs and other	[3]	10	36
Restructuring charges and certain acquisition-related costs	[4]	69	46
Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income	[5]	0	13
Implementation costs recorded in our condensed consolidated statements of income as follows:
Implementation costs	[6]	24	26
Total costs associated with acquisitions and cost-reduction/productivity initiatives		117	92
Other (income)/deductions––net [Member]
Restructuring charges:
Net periodic benefit costs recorded in Other (income)/deductions––net		24	6
Cost of sales [Member]
Restructuring charges:
Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income	[5]	5	9
Implementation costs recorded in our condensed consolidated statements of income as follows:
Implementation costs	[6]	10	13
Selling, informational and administrative expenses [Member]
Restructuring charges:
Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income	[5]	0	1
Implementation costs recorded in our condensed consolidated statements of income as follows:
Implementation costs	[6]	15	9
Research and development expenses [Member]
Restructuring charges:
Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income	[5]	(5)	3
Implementation costs recorded in our condensed consolidated statements of income as follows:
Implementation costs	[6]	$ 0	$ 4
[1]	In the first quarter of 2020 , restructuring charges mainly represent asset write-downs and employee termination costs associated with cost reduction initiatives. In the first quarter of 2019 , restructuring charges were primarily associated with cost reduction initiatives and mainly represent asset write-downs, partially offset by the reversal of previously recorded accruals for employee termination costs and asset impairments related to our acquisition of Hospira. The restructuring activities for the first quarter of 2020 are associated with the following: • Biopharma ( $2 million charge); Upjohn ( $13 million charge); and Other ( $41 million charge). The restructuring activities for the first quarter of 2019 are associated with the following: • Biopharma ( $13 million charge); Upjohn ( $13 million credit); and Other ( $10 million charge).
[2]	Transaction costs represent external costs for banking, legal, accounting and other similar services. In the first quarter of 2020, transaction costs relate to our acquisition of Array.
[3]	Integration costs and other represent external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the first quarter of 2020 , integration costs and other were mostly related to our acquisition of Array. In the first quarter of 2019 , integration costs and other were primarily related to our acquisition of Hospira.
[4]	Amounts may not add due to rounding.
[5]	Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
[6]	Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.

Restructuring Charges and Oth_5

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended
		Mar. 29, 2020	Mar. 31, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring charge (credit)	[1]	$ 56	$ 10
Other [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charge (credit)		41	10
Biopharma [Member] | Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charge (credit)		2	13
Upjohn [Member] | Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charge (credit)		$ 13	$ (13)
[1]	In the first quarter of 2020 , restructuring charges mainly represent asset write-downs and employee termination costs associated with cost reduction initiatives. In the first quarter of 2019 , restructuring charges were primarily associated with cost reduction initiatives and mainly represent asset write-downs, partially offset by the reversal of previously recorded accruals for employee termination costs and asset impairments related to our acquisition of Hospira. The restructuring activities for the first quarter of 2020 are associated with the following: • Biopharma ( $2 million charge); Upjohn ( $13 million charge); and Other ( $41 million charge). The restructuring activities for the first quarter of 2019 are associated with the following: • Biopharma ( $13 million charge); Upjohn ( $13 million credit); and Other ( $10 million charge).

Restructuring Charges and Oth_6

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail) - USD ($) $ in Millions		3 Months Ended
		Mar. 29, 2020	Mar. 31, 2019
Restructuring Reserve [Roll Forward]
Balance, December 31, 2019	[1]	$ 933
Provision	[2]	56	$ 10
Utilization and other	[3]	(275)
Balance, March 29, 2020	[4]	714
Employee Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2019	[1]	887
Provision		25
Utilization and other	[3]	(243)
Balance, March 29, 2020	[4]	669
Asset Impairment Charges [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2019	[1]	0
Provision		31
Utilization and other	[3]	(31)
Balance, March 29, 2020	[4]	0
Exit Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2019	[1]	46
Provision		0
Utilization and other	[3]	(1)
Balance, March 29, 2020	[4]	$ 45
[1]	Included in Other current liabilities ( $714 million ) and Other noncurrent liabilities ( $219 million ).
[2]	In the first quarter of 2020 , restructuring charges mainly represent asset write-downs and employee termination costs associated with cost reduction initiatives. In the first quarter of 2019 , restructuring charges were primarily associated with cost reduction initiatives and mainly represent asset write-downs, partially offset by the reversal of previously recorded accruals for employee termination costs and asset impairments related to our acquisition of Hospira. The restructuring activities for the first quarter of 2020 are associated with the following: • Biopharma ( $2 million charge); Upjohn ( $13 million charge); and Other ( $41 million charge). The restructuring activities for the first quarter of 2019 are associated with the following: • Biopharma ( $13 million charge); Upjohn ( $13 million credit); and Other ( $10 million charge).
[3]	Includes adjustments for foreign currency translation.
[4]	Included in Other current liabilities ( $532 million ) and Other noncurrent liabilities ( $182 million ).

Restructuring Charges and Oth_7

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail) - USD ($) $ in Millions	Mar. 29, 2020		Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	$ 714	[1]	$ 933	[2]
Other Current Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	532		714
Other Noncurrent Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	$ 182		$ 219
[1]	Included in Other current liabilities ( $532 million ) and Other noncurrent liabilities ( $182 million ).
[2]	Included in Other current liabilities ( $714 million ) and Other noncurrent liabilities ( $219 million ).

Other (Income)_Deductions - N_3

Other (Income)/Deductions - Net (Detail) - USD ($) $ in Millions		3 Months Ended
		Mar. 29, 2020	Mar. 31, 2019
Other Income and Expenses [Abstract]
Interest income	[1]	$ (34)	$ (66)
Interest expense	[1]	390	361
Net interest expense		356	295
Royalty-related income		(119)	(89)
Net gains on asset disposals		1	(1)
Net gains recognized during the period on investments in equity securities	[2],[3]	255	(111)
Income from collaborations, out-licensing arrangements and sales of compound/product rights	[4]	(115)	(82)
Net periodic benefit credits other than service costs	[5]	(67)	(40)
Certain legal matters, net		10	4
Certain asset impairments	[6]	0	150
Business and legal entity alignment costs	[7]	0	119
Net losses on early retirement of debt		0	138
GSK Consumer Healthcare JV equity method (income)/loss	[8]	33	0
Other, net	[9]	(132)	(291)
Other (income)/deductions––net	[10]	$ 221	$ 92
[1]	Interest income decreased in the first quarter of 2020 , primarily driven by a lower investment balance and lower short-term interest rates. Interest expense increased in the first quarter of 2020 , mainly as a result of an increased commercial paper balance due to the acquisition of Array.
[2]	The losses in the first quarter of 2020 , include, among other things, unrealized losses of $134 million related to our investment in Allogene. The gains in the first quarter of 2019 included, among other things, unrealized gains of $43 million related to our investment in Allogene. For additional information on investments, see Note 7B .
[3]	The net gains on investments in equity securities are reported in Other (income)/deductions –– net. For additional information, see Note 4 .
[4]	Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In the first quarter of 2020 , mainly includes, among other things, an upfront payment to us of $75 million from our sale of our CK1 assets to Biogen, Inc. In the first quarter of 2019 , primarily included $60 million in milestone income from Mylan Pharmaceuticals Inc. related to the FDA’s approval and launch of Wixela Inhub ® , a generic of Advair Diskus ® .
[5]	For additional information, see Note 10 .
[6]	In the first quarter of 2019 , primarily included intangible asset impairment charges of $130 million composed of: (i) $90 million related to WRDM IPR&D, for a pre-clinical stage asset from our acquisition of Bamboo for gene therapies for the potential treatment of patients with certain rare diseases, which was the result of a determination to not use certain Bamboo IPR&D acquired in future rare disease development and (ii) $40 million related to a Biopharma developed technology right, acquired in connection with our acquisition of King, for government defense products and reflects, among other things, updated commercial forecasts including manufacturing cost assumptions. In addition, the first quarter of 2019 included other asset impairments of $20 million .
[7]	In the first quarter of 2019, represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services.
[8]	See Note 2B for additional information.
[9]	The first quarter of 2020 includes, among other things, dividend income of $77 million from our investment in ViiV. The first quarter of 2019 included, among other things, credits of $72 million , reflecting the change in the fair value of contingent consideration, and dividend income of $64 million from our investment in ViiV.
[10]	Amounts may not add due to rounding.

Other (Income)_Deductions - N_4

Other (Income)/Deductions - Net - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended
		Mar. 29, 2020	Mar. 31, 2019
Loss Contingencies [Line Items]
Unrealized gain (loss) on equity securities	[1]	$ (274)	$ 106
Intangible asset impairment charge		130
Other asset impairments			20
Change in fair value of contingent consideration			72
ViiV [Member]
Loss Contingencies [Line Items]
Dividend income		77	64
Allogene [Member]
Loss Contingencies [Line Items]
Unrealized gain (loss) on equity securities		(134)	43
Mylan [Member] | Collaborative Arrangement [Member]
Loss Contingencies [Line Items]
Milestone payment received			$ 60
Disposed of by Sale [Member] | CK1 assets sold to Biogen, Inc [Member]
Loss Contingencies [Line Items]
Consideration transferred		75
Biopharma [Member] | Operating Segments [Member] | Developed Technology Rights [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charge		40
Gene Therapies [Member] | WRDM [Member] | In Process Research and Development [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charge		$ 90
[1]	Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of $58 million and upward adjustments of $60 million . Impairments, downward and upward adjustments were not significant in the first quarter of 2020 and 2019 .

Tax Matters - Narrative (Detail

Tax Matters - Narrative (Detail) - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Jul. 31, 2020	Mar. 29, 2020	Mar. 31, 2019
Income Taxes [Line Items]
Effective tax rate for income from continuing operations		12.20%	10.00%
Repatriation tax liability		$ 15,000
Income Taxes Payable [Member]
Income Taxes [Line Items]
Repatriation tax liability		$ 650
Subsequent Event [Member] | Forecast [Member]
Income Taxes [Line Items]
Second installment for repatriation tax	$ 650

Tax Matters (Detail)

Tax Matters (Detail) - USD ($) $ in Millions		3 Months Ended
		Mar. 29, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Foreign currency translation adjustments, net	[1]	$ (252)	$ 27
Unrealized holding gains/(losses) on derivative financial instruments, net		(133)	59
Reclassification adjustments for (gains)/losses included in net income		15	(55)
Derivatives qualifying as hedges, tax, total		(118)	4
Unrealized holding gains/(losses) on available-for-sale securities, net		(6)	5
Reclassification adjustments for losses included in net income		2	1
Available-for-sale securities, tax, total		(5)	7
Benefit plans: actuarial losses, net		(21)	0
Reclassification adjustments related to amortization		15	3
Reclassification adjustments related to settlements, net		9	0
Other		4	(5)
Defined benefit plans, actuarial gain (loss), tax, total		8	(2)
Reclassification adjustments related to amortization of prior service costs and other, net		(11)	(11)
Other		0	0
Pension and other postretirement benefit plans, net prior service cost (credit), tax		(11)	(11)
Tax provision/(benefit) on other comprehensive income/(loss)	[2]	$ (377)	$ 25
[1]	Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.
[2]	Amounts may not add due to rounding.

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail) $ in Millions	3 Months Ended
	Mar. 29, 2020USD ($)
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2019	$ 63,143	[1]
Balance, March 29, 2020	65,026	[1]
Accumulated Other Comprehensive Income (Loss) [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2019	(11,640)
Other comprehensive income/(loss)	(1,490)	[2]
Balance, March 29, 2020	(13,131)
Foreign Currency Translation Adjustment [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2019	(5,952)
Other comprehensive income/(loss)	(1,020)	[2]
Balance, March 29, 2020	(6,973)
Derivative Financial Instruments [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2019	20
Other comprehensive income/(loss)	(364)	[2]
Balance, March 29, 2020	(344)
Cash flow hedge gain to be reclassified within twelve months	294
Available-For-Sale Securities [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2019	(35)
Other comprehensive income/(loss)	(32)	[2]
Balance, March 29, 2020	(67)
Actuarial Gains/(Losses) [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2019	(6,257)
Other comprehensive income/(loss)	(39)	[2]
Balance, March 29, 2020	(6,296)
Prior Service (Costs)/Credits and Other [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2019	584
Other comprehensive income/(loss)	(35)	[2]
Balance, March 29, 2020	549
GSK Consumer Healthcare [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax	$ 1,200
[1]	Amounts may not add due to rounding.
[2]	Includes after-tax losses of approximately $1.2 billion related to foreign currency translation adjustments attributable to our equity method investment in GSK Consumer Healthcare (see Note 2B ), partially offset by the results of our net investment hedging program.

Financial Instruments - Financi

Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($) $ in Millions		Mar. 29, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value	[1],[2]	$ 4,190	$ 705
Total other noncurrent assets	[3]	4,166	4,450
Total assets	[3]	166,336	167,489
Total liabilities		1,248	718
Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		10,623	11,176
Total liabilities		1,248	718
Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		2,812	6,687
Total short-term investments		7,002	7,392
Other Current Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		702	465
Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		15	53
Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		688	413
Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value	[4]	1,603	1,902
Available-for-sale debt securities		296	315
Total long-term investments		1,899	2,216
Other Noncurrent Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		490	526
Insurance contracts	[5]	530	575
Total other noncurrent assets		1,020	1,102
Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		134	266
Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		356	261
Other Current Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		109	114
Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		109	114
Other Noncurrent Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		1,139	604
Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		1,139	604
Level 1 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		1,581	1,863
Total liabilities		0	0
Level 1 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Total short-term investments		0	0
Level 1 [Member] | Other Current Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		0	0
Level 1 [Member] | Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		0	0
Level 1 [Member] | Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		0	0
Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value	[4]	1,581	1,863
Available-for-sale debt securities		0	0
Total long-term investments		1,581	1,863
Level 1 [Member] | Other Noncurrent Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		0	0
Insurance contracts	[5]	0	0
Total other noncurrent assets		0	0
Level 1 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		0	0
Level 1 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		0	0
Level 1 [Member] | Other Current Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		0	0
Level 1 [Member] | Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		0	0
Level 1 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		0	0
Level 1 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		0	0
Level 2 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets		9,042	9,313
Total liabilities		1,248	718
Level 2 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		2,812	6,687
Total short-term investments		7,002	7,392
Level 2 [Member] | Other Current Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		702	465
Level 2 [Member] | Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		15	53
Level 2 [Member] | Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative assets		688	413
Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value	[4]	22	39
Available-for-sale debt securities		296	315
Total long-term investments		318	354
Level 2 [Member] | Other Noncurrent Assets [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		490	526
Insurance contracts	[5]	530	575
Total other noncurrent assets		1,020	1,102
Level 2 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		134	266
Level 2 [Member] | Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative assets		356	261
Level 2 [Member] | Other Current Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		109	114
Level 2 [Member] | Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current derivative liabilities		109	114
Level 2 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		1,139	604
Level 2 [Member] | Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Noncurrent derivative liabilities		1,139	604
Money market funds [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value		4,190	705
Money market funds [Member] | Level 1 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value		0	0
Money market funds [Member] | Level 2 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities with readily determinable fair value		4,190	705
Government and agency - non U.S. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		1,989	4,863
Government and agency - non U.S. [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		1,989	4,863
Government and agency - non U.S. [Member] | Level 1 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Government and agency - non U.S. [Member] | Level 2 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		1,989	4,863
Government and agency - U.S. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		302	1,114
Government and agency - U.S. [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		16	811
Government and agency - U.S. [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		285	303
Government and agency - U.S. [Member] | Level 1 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Government and agency - U.S. [Member] | Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Government and agency - U.S. [Member] | Level 2 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		16	811
Government and agency - U.S. [Member] | Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		285	303
Corporate and other [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities	[6]	817	1,025
Corporate and other [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		806	1,013
Corporate and other [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		11	11
Corporate and other [Member] | Level 1 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Corporate and other [Member] | Level 1 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		0	0
Corporate and other [Member] | Level 2 [Member] | Short-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		806	1,013
Corporate and other [Member] | Level 2 [Member] | Long-term Investments [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities		$ 11	$ 11
[1]	As of March 29, 2020 and December 31, 2019 , equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt.
[2]	As of March 29, 2020 and December 31, 2019 , equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt.
[3]	Amounts may not add due to rounding.
[4]	As of March 29, 2020 , long-term equity securities of $155 million and as of December 31, 2019 , long-term equity securities of $176 million were held in restricted trusts for benefits attributable to various U.S. non-qualified employee benefit plans.
[5]	Other noncurrent assets include life insurance policies held in restricted trusts attributable to the funding of various U.S. non-qualified employee benefit plans. The underlying invested assets in these insurance contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions –– net in the consolidated statements of income (see Note 4 ).
[6]	Primarily issued by a diverse group of corporations.

Financial Instruments - Finan_2

Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Detail) - USD ($) $ in Millions	Mar. 29, 2020	Dec. 31, 2019
Recurring [Member]
Footnotes to selected financial assets and liabilities:
Long-term equity securities held in trust	$ 155	$ 176

Financial Instruments - Finan_3

Financial Instruments - Financial Liabilities Not Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Millions	Mar. 29, 2020	Dec. 31, 2019
Carrying Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, excluding the current portion	$ 36,281	$ 35,955
Estimated Fair Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, excluding the current portion	40,062	40,842
Estimated Fair Value [Member] | Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, excluding the current portion	$ 40,062	$ 40,842

Financial Instruments - Total S

Financial Instruments - Total Short-Term and Long-Term Investments and Equity Method Investments (Details) - USD ($) $ in Millions		Mar. 29, 2020	Dec. 31, 2019
Short-term investments
Equity securities with readily determinable fair value	[1],[2]	$ 4,190	$ 705
Available-for-sale debt securities		2,812	6,687
Held-to-maturity debt securities		1,198	1,133
Total Short-term investments	[3]	8,199	8,525
Long-term investments
Equity securities with readily determinable fair values		1,603	1,902
Available-for-sale debt securities		296	315
Held-to-maturity debt securities		40	42
Private equity securities at cost		757	756
Total Long-term investments	[3]	2,696	3,014
Equity-method investments	[3]	15,524	17,133
Total long-term investments and equity-method investments		18,220	20,147
Held-to-maturity cash equivalents		$ 401	$ 163
[1]	As of March 29, 2020 and December 31, 2019 , equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt.
[2]	As of March 29, 2020 and December 31, 2019 , equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt.
[3]	Amounts may not add due to rounding.

Financial Instruments - Investm

Financial Instruments - Investments (Details) - USD ($) $ in Millions		Mar. 29, 2020	Dec. 31, 2019
Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]
Debt securities, amortized cost		$ 4,823	$ 8,380
Debt securities, gross unrealized gains		1	6
Debt securities, gross unrealized losses		(77)	(47)
Available-for-sale securities and held-to-maturity securities		4,746	8,340
Debt securities maturities, within 1 year, fair value		4,410
Debt securities maturities, over 1 to 5 years, fair value		304
Debt securities maturities, over 5 years, fair value		32
Government and agency - non U.S. [Member]
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Available-for-sale debt securities, amortized cost		2,056	4,895
Available-for-sale debt securities, gross unrealized gains		0	6
Available-for-sale debt securities, gross unrealized losses		(67)	(38)
Available-for-sale debt securities, fair value		1,989	4,863
Available-for-sale Securities, Debt Maturities [Abstract]
Available-for-sale securities, debt maturities, within 1 year, fair value		1,989
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value		0
Available-for-sale securities, debt maturities, over 5 years, fair value		0
Available-for-sale debt securities, fair value		1,989	4,863
Debt Securities, Held-to-maturity, Maturity [Abstract]
Held-to-maturity securities, debt maturities, total		1,014	803
Held-to-maturity securities, gross unrealized gains		0	0
Held-to-maturity securities, gross unrealized losses		0	0
Held-to-maturity securities, fair value		1,014	803
Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]
Held-to-maturity securities, debt maturities, within 1 year, fair value		1,010
Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value		0
Held-to-maturity securities, debt maturities, over 5 years, fair value		4
Held-to-maturity securities, debt maturities, total		1,014	803
Government and agency - U.S. [Member]
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Available-for-sale debt securities, amortized cost		305	1,120
Available-for-sale debt securities, gross unrealized gains		0	0
Available-for-sale debt securities, gross unrealized losses		(4)	(6)
Available-for-sale debt securities, fair value		302	1,114
Available-for-sale Securities, Debt Maturities [Abstract]
Available-for-sale securities, debt maturities, within 1 year, fair value		16
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value		285
Available-for-sale securities, debt maturities, over 5 years, fair value		0
Available-for-sale debt securities, fair value		302	1,114
Corporate and other [Member]
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Available-for-sale debt securities, amortized cost	[1]	823	1,027
Available-for-sale debt securities, gross unrealized gains	[1]	0	0
Available-for-sale debt securities, gross unrealized losses	[1]	(6)	(2)
Available-for-sale debt securities, fair value	[1]	817	1,025
Available-for-sale Securities, Debt Maturities [Abstract]
Available-for-sale securities, debt maturities, within 1 year, fair value	[1]	807
Available-for-sale securities, debt maturities, over 1 to 5 years, fair value	[1]	11
Available-for-sale securities, debt maturities, over 5 years, fair value	[1]	0
Available-for-sale debt securities, fair value	[1]	817	1,025
Time deposits and other [Member]
Debt Securities, Held-to-maturity, Maturity [Abstract]
Held-to-maturity securities, debt maturities, total		624	535
Held-to-maturity securities, gross unrealized gains		0	0
Held-to-maturity securities, gross unrealized losses		0	0
Held-to-maturity securities, fair value		624	535
Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]
Held-to-maturity securities, debt maturities, within 1 year, fair value		589
Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value		8
Held-to-maturity securities, debt maturities, over 5 years, fair value		28
Held-to-maturity securities, debt maturities, total		$ 624	$ 535
[1]	Primarily issued by a diverse group of corporations.

Financial Instruments - Inves_2

Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 29, 2020	Mar. 31, 2019
Financial Instruments [Abstract]
Net gains recognized during the period on investments in equity securities	[1],[2]	$ 255	$ (111)
Less: Net gains recognized during the period on equity securities sold during the period		(19)	(5)
Net unrealized gains during the reporting period on equity securities still held at the reporting date	[3]	$ 274	$ (106)
[1]	The losses in the first quarter of 2020 , include, among other things, unrealized losses of $134 million related to our investment in Allogene. The gains in the first quarter of 2019 included, among other things, unrealized gains of $43 million related to our investment in Allogene. For additional information on investments, see Note 7B .
[2]	The net gains on investments in equity securities are reported in Other (income)/deductions –– net. For additional information, see Note 4 .
[3]	Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of $58 million and upward adjustments of $60 million . Impairments, downward and upward adjustments were not significant in the first quarter of 2020 and 2019 .

Financial Instruments Financial

Financial Instruments Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details) $ in Millions	Mar. 29, 2020USD ($)
Financial Instruments [Abstract]
Cumulative impairment losses and downward price adjustments on equity securities	$ 58
Cumulative upward price adjustments on equity securities	$ 60

Financial Instruments - Short-t

Financial Instruments - Short-term Borrowings (Details) - USD ($) $ in Millions		Mar. 29, 2020	Dec. 31, 2019
Financial Instruments [Abstract]
Commercial paper		$ 14,908	$ 13,915
Current portion of long-term debt, principal amount		334	1,458
Other short-term borrowings, principal amount	[1]	800	860
Total short-term borrowings, principal amount		16,042	16,233
Net fair value adjustments related to hedging and purchase accounting		3	5
Net unamortized discounts, premiums and debt issuance costs		(38)	(43)
Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted	[2]	$ 16,007	$ 16,195
[1]	Other short-term borrowings primarily include cash collateral. For additional information, see Note 7E .
[2]	Amounts may not add due to rounding.

Financial Instruments - Long-Te

Financial Instruments - Long-Term Debt - New Issuances (Details) - Senior Notes [Member] $ in Millions	Mar. 29, 2020USD ($)
Debt Instrument [Line Items]
Principal	$ 1,250	[1]
Effective interest rate	2.67%
2.625% notes [Member]
Debt Instrument [Line Items]
Principal	$ 1,250	[2]
Stated interest rate	2.625%
[1]	The effective interest rate for the notes at issuance was 2.67% .
[2]	Fixed rate notes may be redeemed by us at any time, in whole, or in part, at a redemption price plus accrued and unpaid interest.

Financial Instruments - Long-_2

Financial Instruments - Long-Term Debt (Details) - USD ($) $ in Millions		Mar. 29, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Net fair value adjustments related to hedging and purchase accounting		$ 3	$ 5
Net unamortized discounts, premiums and debt issuance costs		(38)	(43)
Total long-term debt, carried at historical proceeds, as adjusted	[1]	36,281	35,955
Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above)	[1]	337	1,462
Unsecured Debt [Member]
Debt Instrument [Line Items]
Total long-term debt, principal amount		34,778	34,820
Net fair value adjustments related to hedging and purchase accounting		1,671	1,305
Net unamortized discounts, premiums and debt issuance costs		(173)	(176)
Other long-term debt		5	5
Total long-term debt, carried at historical proceeds, as adjusted		36,281	35,955
Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above)		$ 337	$ 1,462
[1]	Amounts may not add due to rounding.

Financial Instruments - Long-_3

Financial Instruments - Long-Term Debt Narrative (Details) $ in Millions	Mar. 29, 2020USD ($)
Unsecured Debt [Member] | Senior Notes Due 2047 [Member]
Debt Instrument [Line Items]
Repurchase amount	$ 1,065

Financial Instruments - Fair Va

Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details) - USD ($) $ in Millions		Mar. 29, 2020	Dec. 31, 2019
Derivative [Line Items]
Asset		$ 1,192	$ 992
Liability		1,248	718
Derivatives designated as hedging instruments [Member]
Derivative [Line Items]
Asset		1,103	909
Liability		1,150	662
Derivatives designated as hedging instruments [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Notional	[1]	23,877	25,193
Asset	[1]	955	591
Liability	[1]	1,150	662
Derivatives designated as hedging instruments [Member] | Interest rate contracts [Member]
Derivative [Line Items]
Notional		1,995	6,645
Asset		148	318
Liability		0	0
Derivatives not designated as hedging instruments [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Notional		13,402	19,623
Asset		89	82
Liability		97	55
Inventory sales [Member] | Derivatives designated as hedging instruments [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Notional	[1]	$ 5,300	$ 5,900
[1]	The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $5.3 billion as of March 29, 2020 and $5.9 billion as of December 31, 2019.

Financial Instruments - Derivat

Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 29, 2020	Mar. 31, 2019
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[1]	$ (501)	$ 267
All other, net - Amount of Gains/(Losses) Recognized in OCI	[2],[3],[4]	(1)	1
Amount of Gains/(Losses) Recognized in OCI	[2],[3]	83	404
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[1],[5]	(19)	263
OID [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[3]	(59)	(120)
Other (Income) Deductions And Cost Of Sales [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[3],[4]	0	0
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[3]	23	286
Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[2],[3],[6]	(529)	210
Amount of Gains/(Losses) Recognized in OCI	[2],[3]	384	23
Designated as Hedging Instrument [Member] | Foreign currency short-term borrowings [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[2],[3],[7]	8	35
Designated as Hedging Instrument [Member] | Foreign currency long-term debt [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OCI	[2],[3],[7]	45	38
Designated as Hedging Instrument [Member] | OID [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[3]	0	0
Hedged item	[3]	0	0
Designated as Hedging Instrument [Member] | OID [Member] | Interest rate contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[3]	386	329
Hedged item	[3]	(386)	(329)
Designated as Hedging Instrument [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[3],[6]	(46)	209
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[3]	0	0
Designated as Hedging Instrument [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign currency short-term borrowings [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[3],[7]	0	0
Designated as Hedging Instrument [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign currency long-term debt [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS	[2],[3],[7]	0	0
Derivative Financial Instruments Not Designated as Hedges [Member] | OID [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of Gains/(Losses) Recognized in OID	[3]	(59)	(120)
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount excluded from effectiveness testing	[2],[3],[4]	29	56
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount excluded from effectiveness testing	[2],[3],[4]	27	54
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount excluded from effectiveness testing	[2],[3],[4]	147	41
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount excluded from effectiveness testing	[2],[3],[4]	$ 41	$ 24
[1]	Amounts may not add due to rounding.
[2]	For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in Other comprehensive income/(loss)––Unrealized holding gains/(losses) on derivative financial instruments, net . For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the gains and losses are included in Other comprehensive income/(loss)––Foreign currency translation adjustments, net.
[3]	OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of income . COS = Cost of Sales, included in Cost of sales in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income .
[4]	The amounts reclassified from OCI were reclassified into OID.
[5]	Reclassified into Other (income)/deductions—net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Other (income)/deductions—net and Cost of sales, see Note 7E. Financial Instruments: Derivative Financial Instruments and Hedging Activities.
[6]	The amounts reclassified from OCI into COS were a net gain of $70 million in the first quarter of 2020 and a net gain of $44 million in the first quarter of 2019. The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $220 million within the next 12 months into Cost of sales. The maximum length of time over which we are hedging future foreign exchange cash flow relates to our $1.8 billion U.K. pound debt maturing in 2043.
[7]	Long-term debt includes foreign currency long-term borrowings with carrying values of $1.9 billion as of March 29, 2020 , which are used as hedging instruments in net investment hedges. The following table provides the amounts recorded in our condensed consolidated balance sheet related to cumulative basis adjustments for fair value hedges: March 29, 2020 December 31, 2019 Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount (MILLIONS OF DOLLARS) Carrying Amount of Hedged Assets/Liabilities (a) Active Hedging Relationships Discontinued Hedging Relationships Carrying Amount of Hedged Assets/Liabilities (a) Active Hedging Relationships Discontinued Hedging Relationships Long-term investments $ 45 $ — $ — $ 45 $ — $ — Long-term debt 2,027 134 1,196 7,092 266 690

Financial Instruments - Deriv_2

Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 29, 2020	Mar. 31, 2019
Derivative [Line Items]
Amount of (Gains)/Losses Reclassified from OCI into OID and COS	[1],[2]	$ 19	$ (263)
Pre-tax gain expected to be reclassified within the next 12 months		220
Unsecured Debt [Member]
Derivative [Line Items]
Long-term debt		1,800
Foreign currency long-term debt [Member]
Derivative [Line Items]
Long-term debt		1,900
Designated as Hedging Instrument [Member] | Cost of sales [Member] | Foreign exchange contracts [Member]
Derivative [Line Items]
Amount of (Gains)/Losses Reclassified from OCI into OID and COS		$ (70)	$ (44)
[1]	Amounts may not add due to rounding.
[2]	Reclassified into Other (income)/deductions—net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Other (income)/deductions—net and Cost of sales, see Note 7E. Financial Instruments: Derivative Financial Instruments and Hedging Activities.

Financial Instruments - Cumulat

Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details) - USD ($) $ in Millions		Mar. 29, 2020	Dec. 31, 2019
Long-term investments [Member]
Derivative [Line Items]
Carrying Amount of Actively Hedged Assets	[1]	$ 45	$ 45
Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Asset		0	0
Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Asset		0	0
Long-term debt [Member]
Derivative [Line Items]
Carrying Amount of Actively Hedged Liabilities	[1]	2,027	7,092
Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability		134	266
Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability		$ 1,196	$ 690
[1]	Carrying amounts exclude the cumulative amount of fair value hedging adjustments.

Financial Instruments - Deriva

Financial Instruments - Derivative Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2020	Feb. 23, 2020
Derivative [Line Items]
Derivatives in a net liability position	$ 1,100
Collateral posted		$ 463
Cash collateral received	$ 791
Foreign exchange contracts [Member]
Derivative [Line Items]
Derivative term of contract	2 years

Financial Instruments - Credit

Financial Instruments - Credit Risk (Details) $ in Billions	3 Months Ended
	Mar. 29, 2020USD ($)
Bank sector [Member]
Concentration Risk [Line Items]
Maximum exposure, amount	$ 1.3

Inventories (Detail)

Inventories (Detail) - USD ($) $ in Millions		Mar. 29, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Finished goods		$ 2,703	$ 2,750
Work-in-process		4,962	4,743
Raw materials and supplies		757	790
Inventories	[1],[2]	8,423	8,283
Noncurrent inventories not included above	[3]	$ 720	$ 714
[1]	The change from December 31, 2019 reflects increases for certain products, including inventory build for new product launches, market demand and network strategy, partially offset by a decrease due to foreign exchange.
[2]	Amounts may not add due to rounding.
[3]	Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.

Identifiable Intangible Asset_3

Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Detail) - USD ($) $ in Millions		Mar. 29, 2020	Dec. 31, 2019
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets		$ 8,982	$ 8,983
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		91,221	91,425
Finite-lived intangible assets, accumulated amortization	[1]	(65,738)	(65,037)
Finite-lived intangible assets, net		25,482	26,387
Intangible assets, gross carrying amount	[1]	100,203	100,408
Finite-lived intangible assets, accumulated amortization	[1]	(65,738)	(65,037)
Identifiable Intangible Assets, less Accumulated Amortization	[1],[2]	34,464	35,370
Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets		1,991	1,991
In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	[1]	5,918	5,919
License Agreements and Other [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets		1,073	1,073
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		88,519	88,730
Finite-lived intangible assets, accumulated amortization		(63,783)	(63,106)
Finite-lived intangible assets, net		24,736	25,625
Finite-lived intangible assets, accumulated amortization		(63,783)	(63,106)
Brands [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		922	922
Finite-lived intangible assets, accumulated amortization		(749)	(741)
Finite-lived intangible assets, net		173	181
Finite-lived intangible assets, accumulated amortization		(749)	(741)
License Agreements and Other [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		1,779	1,772
Finite-lived intangible assets, accumulated amortization		(1,206)	(1,191)
Finite-lived intangible assets, net		574	582
Finite-lived intangible assets, accumulated amortization		$ (1,206)	$ (1,191)
[1]	The decrease in I dentifiable intangible assets, less accumulated amortization , is primarily due to amortization.
[2]	Amounts may not add due to rounding.

Identifiable Intangible Asset_4

Identifiable Intangible Assets and Goodwill - Finite-lived Intangible Assets Percentage of Total Intangibles (Details)	Mar. 29, 2020
Operating Segments [Member] | Developed Technology Rights [Member] | Biopharma [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	99.00%
Operating Segments [Member] | Developed Technology Rights [Member] | Upjohn [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	1.00%
Operating Segments [Member] | Brands [Member] | Biopharma [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	100.00%
Operating Segments [Member] | Brands [Member] | Upjohn [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
Operating Segments [Member] | Licensing Agreements And Other [Member] | Biopharma [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	97.00%
Operating Segments [Member] | Licensing Agreements And Other [Member] | Upjohn [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	1.00%
WRDM [Member] | Segment Reconciling Items [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
WRDM [Member] | Segment Reconciling Items [Member] | Brands [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
WRDM [Member] | Segment Reconciling Items [Member] | Licensing Agreements And Other [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	1.00%

Identifiable Intangible Asset_5

Identifiable Intangible Assets and Goodwill - Indefinite-lived Intangible Assets Percentage of Total Intangibles (Details)	Mar. 29, 2020
Biopharma [Member] | Operating Segments [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	42.00%
Biopharma [Member] | Operating Segments [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	95.00%
Biopharma [Member] | Operating Segments [Member] | Licensing Agreements And Other [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	100.00%
Upjohn [Member] | Operating Segments [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	58.00%
Upjohn [Member] | Operating Segments [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
Upjohn [Member] | Operating Segments [Member] | Licensing Agreements And Other [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
WRDM [Member] | Segment Reconciling Items [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
WRDM [Member] | Segment Reconciling Items [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	5.00%
WRDM [Member] | Segment Reconciling Items [Member] | Licensing Agreements And Other [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%

Identifiable Intangible Asset_6

Identifiable Intangible Assets and Goodwill - Narrative (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2020	Mar. 31, 2019
Finite-Lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expense for finite-lived intangible assets	$ 897	$ 1,200

Identifiable Intangible Asset_7

Identifiable Intangible Assets and Goodwill - Goodwill (Detail) $ in Millions	3 Months Ended
	Mar. 29, 2020USD ($)
Goodwill [Roll Forward]
Balance, December 31, 2019	$ 58,653	[1]
Other	(151)	[2]
Balance, March 29, 2020	58,502	[1]
Operating Segments [Member] | Biopharma [Member]
Goodwill [Roll Forward]
Balance, December 31, 2019	48,202
Other	(122)	[2]
Balance, March 29, 2020	48,081
Operating Segments [Member] | Upjohn [Member]
Goodwill [Roll Forward]
Balance, December 31, 2019	10,451
Other	(30)	[2]
Balance, March 29, 2020	$ 10,421
[1]	Amounts may not add due to rounding.
[2]	Represents the impact of foreign exchange.

Pension and Postretirement Be_3

Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2020	Mar. 31, 2019
Pension Plan [Member] | U.S. [Member] | Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 0	$ 0
Interest cost	131	157
Expected return on plan assets	(252)	(223)
Amortization of:
Actuarial losses	32	37
Prior service costs/(credits)	(1)	(1)
Settlements	14	1
Special termination benefits	0	0
Defined benefit plan, net periodic benefit cost	(76)	(28)
Pension Plan [Member] | International [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	36	32
Interest cost	42	54
Expected return on plan assets	(78)	(80)
Amortization of:
Actuarial losses	31	20
Prior service costs/(credits)	(1)	(1)
Settlements	1	0
Special termination benefits	0	0
Defined benefit plan, net periodic benefit cost	32	25
Supplemental Employee Retirement Plan [Member] | U.S. [Member] | Non-Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	0	0
Interest cost	10	12
Expected return on plan assets	0	0
Amortization of:
Actuarial losses	4	2
Prior service costs/(credits)	0	0
Settlements	38	0
Special termination benefits	1	6
Defined benefit plan, net periodic benefit cost	52	20
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	10	9
Interest cost	13	19
Expected return on plan assets	(9)	(8)
Amortization of:
Actuarial losses	0	1
Prior service costs/(credits)	(43)	(45)
Settlements	0	0
Special termination benefits	0	0
Defined benefit plan, net periodic benefit cost	$ (30)	$ (23)

Pension and Postretirement Be_4

Pension and Postretirement Benefit Plans (Detail) - USD ($) $ in Millions		3 Months Ended	6 Months Ended
		Mar. 29, 2020	Dec. 31, 2020
Pension Plan [Member] | U.S. [Member] | Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the three months ended March 29, 2020		$ 3
Expected contributions from our general assets during 2020	[1]	1,276
Pension Plan [Member] | International [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the three months ended March 29, 2020		46
Expected contributions from our general assets during 2020	[1]	186
Supplemental Employee Retirement Plan [Member] | U.S. [Member] | Non-Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the three months ended March 29, 2020		132
Expected contributions from our general assets during 2020	[1]	228
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the three months ended March 29, 2020		45
Expected contributions from our general assets during 2020	[1]	$ 155
Forecast [Member] | Pension Plan [Member] | U.S. [Member] | Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the three months ended March 29, 2020			$ 1,250
[1]	Contributions expected to be made for 2020 are inclusive of amounts contributed during the three months ended March 29, 2020 . The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments. For the U.S. qualified plans, we plan to make a $1.25 billion voluntary contribution in the second half of 2020.

Earnings Per Common Share Att_3

Earnings Per Common Share Attributable to Common Shareholders (Details) - USD ($) shares in Millions, $ in Millions		3 Months Ended
		Mar. 29, 2020	Mar. 31, 2019
EPS Numerator––Basic
Income from continuing operations	[1]	$ 3,410	$ 3,889
Less: Net income attributable to noncontrolling interests		9	6
Income from continuing operations attributable to Pfizer Inc.		3,401	3,884
Less: Preferred stock dividends––net of tax		0	0
Income from continuing operations attributable to Pfizer Inc. common shareholders		3,401	3,883
Discontinued operations––net of tax	[1]	0	0
Net income attributable to Pfizer Inc. common shareholders		3,401	3,883
EPS Numerator––Diluted
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions		3,401	3,884
Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions		0	0
Net income attributable to Pfizer Inc. common shareholders and assumed conversions		$ 3,401	$ 3,884
EPS Denominator
Weighted-average number of common shares outstanding––Basic (shares)	[1]	5,545	5,635
Common-share equivalents: stock options, stock issuable under employee compensation plans and convertible preferred stock (shares)		68	115
Weighted-average number of common shares outstanding––Diluted (shares)	[1]	5,613	5,750
Equity Option [Member]
EPS Denominator
Anti-dilutive common stock equivalents (shares)	[2]	3	2
[1]	Amounts may not add due to rounding.
[2]	These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Earnings Per Common Share Att_4

Earnings Per Common Share Attributable to Common Shareholders - Narrative (Details) - $ / shares	1 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Earnings Per Share [Abstract]
Cash dividends declared per share (in dollars per share)	$ 0.38	$ 0.36

Contingencies and Certain Com_2

Contingencies and Certain Commitments (Actions In Which We Are The Plaintiff) (Details)

Mar. 29, 2020Patents

Mar. 29, 2020Patents

Jan. 31, 2020Patents

Mar. 31, 2019Patents

Dec. 31, 2018Patents

Jun. 30, 2018Patents

Jan. 31, 2018Patents

Oct. 31, 2017Patents

Mar. 31, 2017Patents

Aug. 31, 2015Patents

Mar. 29, 2020Patents

Apr. 30, 2017PatentsDefendant

Dec. 31, 2014Patents

Precedex Premix [Member] | Hospira Versus Amneal Pharmaceuticals LLC [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly not infringed upon

1

Precedex Premix [Member] | Hospira Versus Amneal Pharmaceuticals LLC [Member] | Settled Litigation [Member]

Gain Contingencies [Line Items]

Number of patents infringed upon

1

Number of allegedly not infringed upon patents due to expire March 2019

1

Number of patents not infringed upon

3

Precedex Premix [Member] | Hospira Versus Fresenius Kabj USA LLC [Member] | Settled Litigation [Member]

Gain Contingencies [Line Items]

Number of patents not infringed upon

2

2

Number of patents found not infringed upon subsequently appealed

1

Precedex Premix [Member] | Hospira Versus Par [Member] | Settled Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly not infringed upon

4

4

Precedex Premix [Member] | Hospira Versus Par Steril Products, LLC, Gland Pharma Limited And Jiangsu Hengrui Medicine Co. [Member] | Settled Litigation [Member]

Gain Contingencies [Line Items]

Number of patents not infringed upon

3

Patent Infringement [Member]

Gain Contingencies [Line Items]

Number of patents which the Patent Trial and Appeal Board refused to initiate proceedings

2

Patent Infringement [Member] | Judicial Ruling [Member]

Gain Contingencies [Line Items]

Number of patents infringed upon

1

Patent Infringement [Member] | Pfizer Versus Ajanta [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

2

Patent Infringement [Member] | Pfizer Versus Generic Companies [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

2

Patent Infringement [Member] | Pfizer Versus Viwit Pharmaceutical Co. Ltd. [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

3

Patent Infringement [Member] | Xeljanz [Member] | Pfizer Versus Zydus [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

3

Patent Infringement [Member] | Eliquis [Member] | Pfizer and BMS Versus Several Generic Manufacturers [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

3

Number of defendants | Defendant

25

Number of patents allegedly infringed upon due to expire December 2019

1

Contingencies and Certain Com_3

Contingencies and Certain Commitments (Actions In Which We Are The Defendant) (Detail) £ in Millions, $ in Millions	1 Months Ended
	Mar. 29, 2020USD ($)lawsuit	Oct. 31, 2018manufacturer	Sep. 30, 2018lagoon	Nov. 30, 2017class_action	Mar. 31, 2015Patents	Mar. 31, 2013lagoon	Dec. 31, 2016GBP (£)
Loss Contingencies [Line Items]
Number of class actions filed | class_action				2
Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member]
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon					6
Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Claims dismissed					4
Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon					2
Hormone Therapy Products [Member] | Class Action Versus Wyeth [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Settlement agreed | $	$ 200
Docetaxel [Member] | Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of defendants other than main defendant | manufacturer		8
Environmental Remediation Litigation [Member]
Loss Contingencies [Line Items]
Number of lagoons | lagoon			2			2
Violation of Antitrust Laws [Member] | Phenytoin Sodium Capsules [Member]
Loss Contingencies [Line Items]
Imposed fine | £							£ 84.2
Minimum [Member] | EpiPen [Member]
Loss Contingencies [Line Items]
Number of lawsuits | lawsuit	1

Contingencies and Certain Com_4

Contingencies and Certain Commitments - Contingent Consideration (Details) - USD ($) $ in Millions	Mar. 29, 2020	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Fair value of contingent consideration	$ 669	$ 711
Contingent consideration liability current	124	160
Contingent consideration liability noncurrent	$ 544	$ 551

Segment, Geographic and Other_3

Segment, Geographic and Other Revenue Information - Narrative (Detail) $ in Millions		7 Months Ended
		Jul. 31, 2019Operating_Segment	Mar. 29, 2020USD ($)	Dec. 31, 2019USD ($)
Segment Reporting [Abstract]
Number of segments | Operating_Segment		3
Assets | $	[1]		$ 166,336	$ 167,489
[1]	Amounts may not add due to rounding.

Segment, Geographic and Other_4

Segment, Geographic and Other Revenue Information (Detail) - USD ($) $ in Millions		3 Months Ended
		Mar. 29, 2020	Mar. 31, 2019
Segment Reporting Information [Line Items]
Revenues	[1]	$ 12,028	$ 13,118
Earnings	[1],[2]	3,885	4,323
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		12,028	12,259
Earnings	[2]	7,920	8,162
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Revenues		0	858
Earnings	[2]	(1,489)	(1,113)
Segment Reconciling Items [Member] | Purchase Accounting Adjustments [Member]
Segment Reporting Information [Line Items]
Revenues		0	0
Earnings	[2]	(812)	(1,038)
Segment Reconciling Items [Member] | Acquisition-Related Costs [Member]
Segment Reporting Information [Line Items]
Revenues		0	0
Earnings	[2]	(13)	(28)
Segment Reconciling Items [Member] | Certain Significant Items [Member]
Segment Reporting Information [Line Items]
Revenues	[3]	0	0
Earnings	[2],[3]	(612)	(382)
Corporate and other unallocated [Member]
Segment Reporting Information [Line Items]
Revenues		0	0
Earnings	[2]	(1,110)	(1,278)
Biopharma [Member]
Segment Reporting Information [Line Items]
Revenues		10,007	9,045
Biopharma [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		10,007	9,045
Earnings	[2]	6,729	5,883
Upjohn [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		2,022	3,214
Earnings	[2]	$ 1,191	$ 2,279
[1]	Amounts may not add due to rounding.
[2]	Income from continuing operations before provision for taxes on income . Biopharma’s earnings include d ividend income of $77 million in the first quarter of 2020 and $64 million in the first quarter of 2019 from our investment in ViiV. For additional information, see Note 4.
[3]	Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.

Segment, Geographic and Other_5

Segment, Geographic and Other Revenue Information - Footnotes (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2020	Mar. 31, 2019
ViiV [Member]
Segment Reporting Information [Line Items]
Dividend income	$ 77	$ 64

Segment, Geographic and Other_6

Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail) - USD ($) $ in Millions		3 Months Ended
		Mar. 29, 2020	Mar. 31, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	$ 12,028	$ 13,118
Percentage Change In Revenue		(8.00%)
U.S. [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 5,651	6,175
Percentage Change In Revenue		(8.00%)
Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[2]	$ 1,921	2,086
Percentage Change In Revenue	[2]	(8.00%)
Developed Rest Of World [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[3]	$ 1,456	1,535
Percentage Change In Revenue	[3]	(5.00%)
Emerging Markets [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[4]	$ 3,001	$ 3,322
Percentage Change In Revenue	[4]	(10.00%)
[1]	Amounts may not add due to rounding.
[2]	Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.5 billion in the first quarter of 2020 and $1.7 billion in the first quarter of 2019 .
[3]	Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.
[4]	Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.

Segment, Geographic and Other_7

Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended
		Mar. 29, 2020	Mar. 31, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	$ 12,028	$ 13,118
Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[2]	1,921	2,086
Euro Member Countries, Euro [Member] | Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 1,500	$ 1,700
[1]	Amounts may not add due to rounding.
[2]	Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.5 billion in the first quarter of 2020 and $1.7 billion in the first quarter of 2019 .

Segment, Geographic and Other_8

Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($) $ in Millions		3 Months Ended
		Mar. 29, 2020	Mar. 31, 2019
Revenue from External Customer [Line Items]
Revenues	[1]	$ 12,028	$ 13,118
Biopharma, Upjohn And Consumer Healthcare Segments [Member]
Revenue from External Customer [Line Items]
Revenues		12,028	13,118
Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Total Alliance revenues [Member]
Revenue from External Customer [Line Items]
Revenues		1,382	1,090
Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Total Biosimilars [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	288	179
Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Total Sterile Injectable Pharmaceuticals [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	1,407	1,237
Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		10,007	9,045
Internal Medicine [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	2,332	2,137
Internal Medicine [Member] | Biopharma [Member] | Eliquis [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	1,300	1,011
Internal Medicine [Member] | Biopharma [Member] | Chantix / Champix [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	270	273
Internal Medicine [Member] | Biopharma [Member] | Premarin family [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	152	168
Internal Medicine [Member] | Biopharma [Member] | BMP2 [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	69	67
Internal Medicine [Member] | Biopharma [Member] | Toviaz [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	60	60
Internal Medicine [Member] | Biopharma [Member] | All other Internal Medicine [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	480	559
Oncology [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		2,435	1,961
Oncology [Member] | Biopharma [Member] | Ibrance [Member]
Revenue from External Customer [Line Items]
Revenues		1,248	1,133
Oncology [Member] | Biopharma [Member] | Xtandi alliance revenues [Member]
Revenue from External Customer [Line Items]
Revenues		209	168
Oncology [Member] | Biopharma [Member] | Sutent [Member]
Revenue from External Customer [Line Items]
Revenues		205	232
Oncology [Member] | Biopharma [Member] | Inlyta [Member]
Revenue from External Customer [Line Items]
Revenues		169	73
Oncology [Member] | Biopharma [Member] | Xalkori [Member]
Revenue from External Customer [Line Items]
Revenues		149	123
Oncology [Member] | Biopharma [Member] | Bosulif [Member]
Revenue from External Customer [Line Items]
Revenues		100	80
Oncology [Member] | Biopharma [Member] | Retacrit [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	89	31
Oncology [Member] | Biopharma [Member] | Braftovi [Member]
Revenue from External Customer [Line Items]
Revenues		37	0
Oncology [Member] | Biopharma [Member] | Mektovi [Member]
Revenue from External Customer [Line Items]
Revenues		37	0
Oncology [Member] | Biopharma [Member] | All other Oncology [Member]
Revenue from External Customer [Line Items]
Revenues		192	122
Hospital [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	2,012	1,827
Hospital [Member] | Biopharma [Member] | Sulperazon [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	187	177
Hospital [Member] | Biopharma [Member] | Zithromax [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	138	104
Hospital [Member] | Biopharma [Member] | Medrol [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	129	120
Hospital [Member] | Biopharma [Member] | Vfend [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	74	85
Hospital [Member] | Biopharma [Member] | Panzyga [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	74	17
Hospital [Member] | Biopharma [Member] | Zyvox [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	70	64
Hospital [Member] | Biopharma [Member] | Fragmin [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	59	60
Hospital [Member] | Biopharma [Member] | Pfizer CentreOne [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5],[6]	152	176
Hospital [Member] | Biopharma [Member] | All other Anti-infectives [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	444	405
Hospital [Member] | Biopharma [Member] | All other Hospital [Member]
Revenue from External Customer [Line Items]
Revenues	[4],[5]	684	620
Vaccines [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		1,611	1,612
Vaccines [Member] | Biopharma [Member] | Prevnar 13/Prevenar 13 [Member]
Revenue from External Customer [Line Items]
Revenues		1,450	1,486
Vaccines [Member] | Biopharma [Member] | Nimenrix [Member]
Revenue from External Customer [Line Items]
Revenues		75	50
Vaccines [Member] | Biopharma [Member] | All other Vaccines [Member]
Revenue from External Customer [Line Items]
Revenues		86	77
Inflammation and Immunology (I&I) [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		978	1,037
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | Xeljanz [Member]
Revenue from External Customer [Line Items]
Revenues		451	423
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | Enbrel (Outside the U.S. and Canada) [Member]
Revenue from External Customer [Line Items]
Revenues		347	451
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | Inflectra/Remsima [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	158	138
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | All other I & I [Member]
Revenue from External Customer [Line Items]
Revenues		22	25
Rare Disease [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		639	470
Rare Disease [Member] | Biopharma [Member] | Vyndaqel/Vyndamax [Member]
Revenue from External Customer [Line Items]
Revenues		231	41
Rare Disease [Member] | Biopharma [Member] | BeneFIX [Member]
Revenue from External Customer [Line Items]
Revenues		121	125
Rare Disease [Member] | Biopharma [Member] | Genotropin [Member]
Revenue from External Customer [Line Items]
Revenues		103	107
Rare Disease [Member] | Biopharma [Member] | ReFacto AF/Xyntha [Member]
Revenue from External Customer [Line Items]
Revenues		89	106
Rare Disease [Member] | Biopharma [Member] | Somavert [Member]
Revenue from External Customer [Line Items]
Revenues		64	59
Rare Disease [Member] | Biopharma [Member] | All other Rare Disease [Member]
Revenue from External Customer [Line Items]
Revenues		31	31
Upjohn [Member] | Upjohn [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	2,022	3,214
Upjohn [Member] | Upjohn [Member] | Lipitor [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	405	622
Upjohn [Member] | Upjohn [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	357	1,186
Upjohn [Member] | Upjohn [Member] | Norvasc [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	197	300
Upjohn [Member] | Upjohn [Member] | Celebrex [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	156	174
Upjohn [Member] | Upjohn [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	127	145
Upjohn [Member] | Upjohn [Member] | Zoloft [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	78	69
Upjohn [Member] | Upjohn [Member] | Effexor [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	77	77
Upjohn [Member] | Upjohn [Member] | EpiPen [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	72	56
Upjohn [Member] | Upjohn [Member] | Xalatan/Xalacom [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	61	62
Upjohn [Member] | Upjohn [Member] | All other Upjohn [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	492	523
Consumer Healthcare [Member] | Consumer Healthcare [Member]
Revenue from External Customer [Line Items]
Revenues	[7]	$ 0	$ 858
[1]	Amounts may not add due to rounding.
[2]	Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit.
[3]	Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.
[4]	Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan). As a result, revenues associated with our Meridian subsidiary, except for product revenues for EpiPen sold in Canada, and Mylan-Japan, are reported in our Upjohn business beginning in the first quarter of 2020. We have reclassified revenues associated with our Meridian subsidiary and Mylan-Japan from the Hospital and Internal Medicine categories to the Upjohn business to conform 2019 product revenues to the current presentation.
[5]	Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. Hospital also includes Pfizer CentreOne (d) . All other Hospital primarily includes revenues from legacy Sterile Injectables Pharmaceuticals (SIP) products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in “All other Anti-infectives”.
[6]	Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements.
[7]	On July 31, 2019 , Pfizer’s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK’s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see Note 2B .

Subsequent Event (Details)

Subsequent Event (Details) - Subsequent Event [Member]	May 04, 2020shares
Subsequent Event [Line Items]
Preferred stock outstanding (in shares)	0
Common Stock [Member]
Subsequent Event [Line Items]
Shares issued upon conversion of convertible perpetual preferred stock (in shares)	1,070,369